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1. 
I. INTRODUCTION 
Substantial information pertaining to the components of human 
serum is known. Since 1937 when Tiselius separated serum proteins 
by electrophoresis into albumin, a-, S-, and y-globulins, at least 
forty distinguishable proteins to date have been demonstrated in 
human serum by immuno-electrophoresis. Probably more serum components 
will be found as the study of the anatomical composition of human 
serum is aided by improvement of known techniques and development 
of new ones. Abnormalities in human serum such as the presence of 
split albumin, the lack of gamma globulin, or increased macroglobulin 
levels have been detected by the immuno-electrophoresis technique. 
Such deviations from the normal anatomy of human serum have led 
to explanations of certain disorders within the human population and 
the latter two are responsible for classification of the immunological 
diseases agammaglobulinemia and macroglobulinemia respectively. When 
an anatomical abnormality is disclosed proper therapy can be admin-
istered to rectify its consequences such as infusion of serum gamma 
globulins to infection prone agammaglobulinemic patients. It is now 
well known that the gamma globulin fraction of serum contains antibodies 
but this fact wasn't known until 1938 when shown by Tiselius and 
Kabat (13). Further studies on the various components of serum 
disclosed that antibodies are mainly y-globulins but comprise a 
heterogeneous group of proteins some of which electrophoretically 
migrate between the S and y regions of serum and thereby are defined 
by a separate term immunoglobulins. The family of immunoglobulins 
2. 
have since been classified into five different classes of antibodies, 
IgM, IgG, IgA, IgD, IgE, by structural, physical and chemical differences. 
In general antibodies possess a high degree of specificity with 
respect to their reactions with homologous antigens. This character-
istic is also used to classify antibodies with respect to the sub-
stance with which they react. Knowledge of the specificity of anti-
bodies has been incorporated into various immunochemical techniques 
for many purposes, a few of which are: identification and localization 
of antigens in tissues, purification of antigens and antibodies, and 
clinical diagnosis of diseases. Early diagnosis of a disease is 
obviously of extreme importance in order to promptly administer 
appropriate medication. Of equal if not more importance is the 
administration of proper prophylactic care in order to prevent the 
onset of disease. Both of these procedures are rapidly becoming 
improved and owe much of their development to the characteristic 
specificity of antibodies. Knowledge of antibody levels and types 
of antibodies in human serum is important from the stand point of 
administration of booster vaccines, immunizations against epidemic 
breakouts, blood transfusion therapy, allergies, and autoimmune dis-
orders. It wasn't until Waldenstrom studied the immunoglobulin levels 
in patients manifesting similar symptoms but of unknown origin that 
he discovered abnormally high IgM levels present in their sera. Why 
these patients develop elevated IgM levels isn't completely understood 
but nevertheless the correlation was so evident that Waldenstrom pro-
posed the term macroglobulinemia for this syndrome. It is proposed 
3. 
that an antibody profile of human serum be undertaken to determine the 
levels and kinds of hemagglutinating antibodies present in normal 
adult serum against various antigens. A study of this nature would 
be a significant addition to the composition of human serum. This 
thesis was undertaken in order that information on this subject could 
be obtained. To test human sera for the presence of antibodies to an 
almost infinite number of possible antigens would be unrealistic. 
Therefore antigens selected for this study include M proteins of various 
group A beta hemolytic streptococci, the group specific polysaccharide 
of the same organisms and erythrocytes of various animal species. In 
addition to determining the antibody levels in normal human serum to 
these antigens, sera from convalescent patients with confirmed rheu-
matic heart and patients with streptococcal pharyngitis were also 
assayed for their antibody levels to these antigens. This last pro-
posal was initiated in order to determine whether the antibody profile 
of normal human serum is significantly different from the profiles of 
serum from the above mentioned diseases. To attain this information, 
passive hemagglutination employing stabilized human 0 erythrocytes 
coated with the antigens was performed. This method affords an anti-
body detection sensitivity of 0.004 µg antibody/ml serum (12), com-
pared with 0.1 µg/ml for the complement fixation assay and 5 µg/ml 
when precipitation experiments are performed (22). This sensitivity 
coupled with the fact that no prior decomplementation of serum is 
necessary to perform hemagglutination with these erythrocytes (12) 
provides an assay for detection of small quantities of antibody 
4. 
including those heat labile at 56 C. Various animal erythrocytes were 
also stabilized and used directly to detect hemagglutinating antibodies 
in the sera. To date no one has employed these erythrocytes for the 
purpose of surveying human sera for the presence of hemagglutinating 
antibody versus heterologous erythrocytes and it was a personal unpub-
lished observation that these stabilized erythrocytes were more sensi-
tive than comparable fresh erythrocytes for the detection of the human 
A, B, 0 blood group substances. Several workers have investigated 
sera from patients with known streptococcal infections for their 
type specific anti-M protein levels (8, 22, 23), and Fox (7) has 
assayed sera of normal adult humans for their type specific antibody 
levels to Ml2 and M24 protein. In each instance passive hemagglu-
tination employing erythrocytes coated with specific M proteins was 
used. These studies however were performed on serum samples pretreated 
to remove cross reactive substances to the specific M protein being 
evaluated. It is emphasized that no attempt was made to discern 
whether the sera used in this study contained type specific antibodies 
to the individual M proteins and erhthrocytes tested. Irrespective 
of the cross reactions present, an antibody profile of normal human 
serum would divulge which substances are or are not recognized by 
human serum. Knowledge of the cross reactive nature of M proteins 
and the ability .. to ascertain type specific antibody responses to them 
is imperative when the etiology of a streptococcal disease is to be 
learned. Once a specific organism manifests itself as the causative 
agent of a particular disease, type specific antibody responses to 
5. 
that organism are also helpful in the diagnosis of the disease. How-
ever if a substance can be found that distinguishes a healthy popula-
tion from one that isn't by virtue of its cross reaction with type 
specific antibodies of debilitated individuals, and if such a substance 
is more readily accessible, more convenient to employ, and capable 
of eliminating laborious techniques compared to the homologous antigen 
imparting type specific immunity, such a. substance would be a tremendous 
aid in diagnostics. To search for such a substance is not a unique 
undertaking for in 1932 Paul and Bunnell (21) discovered that serum 
of patients suffering from the disease infectious mononucleosis con-
tained agglutinins for sheep erythrocytes. This discovery provided 
a diagnostic test for this disease. Furthermore, Springer (24) has 
proposed that human erythrocytes are not the only substances with 
blood group ABO specificity. Closely related antigenic determinants 
are known to exist in microbes. It is also established that chickens 
of many races regularly form human anti-B blood group antibodies at 
about twenty days of age. However, employing the anti-globulin test, 
Springer demonstrated that chickens kept under germ free conditions 
since hatching did not develop anti-B blood group antibodies until 
fed live blood group B-active E. coli 086 • Microbial infections could 
therefore result in the formation of antibodies which may cross react 
with the human blood group substances. To what extent streptococcal 
infections in humans induce agglutinins to various erythrocytes was 
also a topic of this investigation. 
6. 
II. MATERIAL AND METHODS 
Serwn. Fifty normal male adult human whole blood samples were 
collected by venipuncture at Abbott Laboratories and their serum 
was extracted as follows: blood samples were allowed to clot 4 hr 
at 24 C in polycarbonate tubes, then centrifuged 5,000 rev/min for 
30 min at 4 C in a Sorvall RC-2B with an SS-34 rotor. Resulting serum 
and residual red blood cells were decanted from the clot into separate 
polycarbonate tubes and recentrifuged 10,000 rev/min for 1 min at 
4 C in the same centrifuge. The erythrocyte free supernatant sera 
were collected and stored at -20 C until used. 
Normal serum ff Name Blood type 
1. Ap., R. 0 
2. Ba., z. 0 
3. Be., F. 0 
4. Bo., w. A 
5. Bo., J. 0 
6. Br., G. 0 
7. Br., N. A 
8. Ch., B. o. 
9. Co., w. 0 
10. Co., P. A 
11. Em., A. A 
12. Fi., F. A 
13. Ga., J. A 
14. Gl., J. A 
15. Gr., c. A 
16. Ha., G. A 
17. Ha., M. A 
18. He., M. 0 
19. Hi., A. B 
20. Ho., c. 0 
21. Jo., P. 0 
22. Ka., G. B 
23. Ke., E. A 
24. Ky., H. A 
25. Lu., R. A 
26. Ma., J. 0 
7. 
Normal serum II Name Blood type 
27. McC., B. 0 
28. McD., B. 0 
29. Mi., D. 0 
30. Ne., D. 0 
31. No., c. 0 
32. Oh., R. AB 
33. Or., T. A 
34. Pe., J. 0 
35. Pr., A. A 
36. Pt., T. A 
37. Rai., J. A 
38. Rai., H. A 
39. Ram., s. 0 
40. Ran., H. B 
41. Sa., J. 0 
42. Se., R. B 
43. Sn., H. A 
44. St.' H. A 
45. St.' w. A 
46. Su., c. 0 
47. Ti.' F. B 
48. We., G. A 
49. We., L. AB 
50. Wi., D. 0 
Ten serum samples from patients with diagnosed streptococcal pharyngitis 
were donated by Dr. Aronovitz (Atlanta, Georgia). All sera are from 
patients who had documented streptococcal pharyngitis 31 days before 
specimens were drawn and 31 days after beginning 10 days of treatment 
with either Penicillin G or Erythromycin. Patients range in age from 
2-14 years old. 
Pharyngitis serum II Name 
1. As., K. 
2. Ba., K. 
3. Du., R. 
4. Fo., w. 
5. Jo.' R. 
6. Le., F. 
7. Ma., R. 
8. 
Pharyngitis serum· fl Name 
8. Mc., T. 
9. Su., T. 
10. Wr., J. 
160 serum samples from thirty patients with diagnosed rheumatic heart 
were donated by Dr. Paterson (Northwestern University, Evanston, 
Illinois). 
Patient II Name Age Sample fl Date of Sample 
1. Ai., G. 28 1. 12-13-67 
2. 2-28-68 
3. 5-8-68 
4. 2-12-69 
5. 4-30-69 
6. 10-29-69 
7. 12-18-69 
8. 2-18-70 
9. 5-27-70 
10. 8-26-70 
2. Ba., A. 31 11. 1-22-68 
12. 1-24-68 
13. 8-7-68 
14. 10-30-68 
15. 5-28-69 
16. 10-15-69 
17. 1-21-70 
18. 4-15-70 
3. Bl., R. 24 19. 8-7-68 
20. 10-30-68 
21. 2-19-69 
22. 5-14-69 
23. 8-6-69 
24. 12-3-69 
25. 2-25-70 
26. 5-20-70 
27. 1-6-71 
4. Bu., s. 28. 10-29-69 
5. Ca., L. 20 29. 3-13-68 
30. 9-4-68 
31. 11-4-68 
32. 3-12-69 
33. 6-4-69 
34. 11-19-69 
9. 
Patient ff Name .Age Sample II Date of Sample 
35. 1-6-70 
36. 2-11-70 
6. Ce., L. 37. 5-6-70 
38. 7-29-70 
39. 10-21-70 
7. Ci.' s. 22 40. 2-14-68 
41. 5-8-68 
42. 2-12-69 
43. 3-5-69 
44. 6-25-69 
45. 9-17-69 
46. 12-10-69 
47. 3-4-70 
48. 5-27-70 
49. 8-18-70 
50. 12-30-70 
8. Do., J. 19 51. 3-13-68 
52. 6-26-68 
53. 10-2-68 
54. 12-18-68 
55. 6-4-69 
56. 11-19-69 
57. 2-4-70 
58. 4-22-70 
59. 10-21-70 
9. Fe., M. 17 60. 10-29-68 
61. 2-18-70 
62. 5-13-70 
63. 8-5-70 
64. 10-28-70 
10. Fu., D. 18 65. 7-30-70 
66. 10-15-69 
67. 2-18-70 
68. 6-10-70 
69. 9-30-70 
70. 10-21-70 
71. 12-16-70 
11. Ga., F. 22 72. 1-22-69 
73. 2-19-69 
74. 5-14-69 
75. 8-13-69 
76. 11-5-69 
77. 2-4-70 
78. 5-6-70 
12. Go., D. 17 79. 8-28-68 
80. 11-13-68 
81. 2-19-69 
82. 8-20-69 
10. 
Patient ti Name Age Sample ti Date of Sample 
13. Hu., K. 18 83. 2-7-68 
84. 2-21-68 
85. 5-22-68 
14. Ja.' D. 24 86. 10-9-68 
15. Jo.' A. 87. 3-4-70 
88. 6-3-70 
89. 11-18-70 
16. Ma., R. 16 90. 3-19-69 
91. 6-25-69 
92. 11-19-69 
17. Mc., s. 93. 1-14-70 
94. 6-3-70 
95. 9-30-70 
18. Mi., H. 22 96. 4-2-69 
97. 6-25-69 
98. 10-15-69 
99. 3-18-70 
19. Mo., M. 27 100. 1-24-68 
101. 2-19-69 
102. 3-19-69 
103. 7-2-69 
104. 2-4-70 
105. 3-25-70 
106. 7-29-70 
20. Mo., G. 19 107. 7-3-68 
108. 10-2-68 
109. 12-18-68 
110. 2-4-70 
111. 6-17-70 
21. Ne., E. 25 112. 7-9-69 
113. 11-26-69 
114. 6-3-70 
115. 7-22-70 
22. Re., J. 19 116. 1-31-68 
117. 4-24-68 
118. 12-18-68 
23. Ro., c. 36 119. 1-17-68 
120. 4-10-68 
121. 12-11-68 
122. 11-26-69 
123. 3-25-70 
124. 4-22-70 
125. 6-17-70 
126. 9-23-70 
127. 9-30-70 
128. 1-6-71 
24. Ro., G. 23 129. 1-24-68 
130. 7-5-68 
r 
Patient If Name 
24. Ro., G. 
25. Si., R. 
26. Su., R. 
27. Va., R. 
28. Vi., A. 
29. Wo., J. 
30. Wo., A. 
23 
16 
18 
26 
28 
Sample If 
131. 
132. 
133. 
134. 
135. 
136. 
137. 
138. 
139. 
140. 
141. 
142. 
143. 
144. 
145. 
146. 
147. 
148. 
149. 
150. 
151. 
152. 
153. 
154. 
155. 
156. 
157. 
158. 
159. 
160. 
Date of Sample 
10-23-68 
12-18-68 
5-14-69 
6-11-69 
1-14-70 
4-20-70 
6-15-70 
10-28-70 
12-16-70 
7-10-68 
1-8-69 
3-5-69 
1-10-68 
3-13-68 
5-14-69 
12-18-68 
3-26-69 
9-10-69 
4-15-70 
6-3-70 
10-28-70 
3-12-69 
8-27-69 
1-24-68 
6-5-68 
6-18-69 
10-15-69 
1-7-70 
4-1-70 
11. 
Prior to investigative use normal, pharyngitis, and rheumatic heart 
sera were further treated as follows. Individual sera were layered 
over with 0.9% NaCl which serves as an intermediate layer between lipid 
and serum during ultracentrifugation. Centrifugation of the sera was 
performed in a Feck.man type 30 rotor at 29,000 rev/min for 2 hr at 
4 C. The lipid and saline layers were then carefully aspirated from the 
serum. 
Erythrocytes. Blood samples were collected in an equal volume 
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of Alsever's solution (14). RBC were washed five times with ten 
times volume of 0.11 M phosphate buffer pH 7.2. Centrifugation for 
washing was 1,500 rev/min for 4 min at 4 C in an International centri-
fuge with #269 rotor. Erythrocytes of the following animals were 
collected and washed: porcine (PE), rabbit, (RE), sheep (SE), 
human 0 (HE), duck (DUE), turtle (TE), baby chicken (BCE), adult 
chicken (CE), rat (RaE), guinea pig (GPE), horse (HOE), dog (DoE), 
goat (GE), and bovine (BE). 
Double aldehyde stabilization of erythrocytes. Erythrocytes 
were stabilized by pyruvic aldehyde and f orrnaldehyde according to the 
method of Hirata (12). With continuous magnetic stirring at 24 C, 
one volume of 3% pyruvic aldehyde solution (Aldrich Chern. Co., Inc., 
Milwaukee, Wisc., Cat. #13836-3) in 0.11 M phosphate buffer pH 7.2 
was added to one volume of an 8% erythrocyte suspension in the same 
buffer pH 7.2 was added to one volume of an 8% erythrocyte suspension 
in the same buffer. The mixture was magnetic stirred for 18 hr at 
24 C then filtered through 4 thicknesses of surgical gauze and washed 
five times with ten times volume phosphate buffer. These pyruvic 
aldehyde treated erythrocytes were then resuspended to 8% in phosphate 
buff er and retreated as above using 3% formaldehyde solution (Mallin-
ckrodt, St. Louis. Mo., Cat. #5016) in phosphate buffer. Upon completion 
of treatment the formaldehyde-pyruvic aldehyde-erythrocytes were either 
stored lyopyilized in 15% sucrose or as a ten percent suspension in 
phosphate buffer at 4 C. Stabilized human erythrocytes are abbreviated 
FPHE, with FP prefix then employed for all other erythrocytes so treated. 
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M-proteins. The M proteins of group A beta hemolytic streptococci 
type 1, 3, 4, 5, 6, 12, 14, and 29 were used for this study. Ml, 
M3, MS, M6, Ml2, and Ml4 were obtained at Abbott Laboratories (No. 
Chicago, Ill.). They were prepared according to a modified version 
of Fox et al. (7). To summarize, the streptococci were hot acid 
extracted at pH 2 for their M protein which was then precipitated by 
33 to 60 percent saturation of ammonium sulfate. After dialysis 
against phosphate buffered saline (PBS), the M proteins were eluted at 
about pH 5.5 from a carboxymethyl cellulose column equilibrated at 
pH 4.0. They were then lyophilized and reconstituted with PBS to a 
concentration of 6 mg/ml determined by biuret using bovine serum albumin 
as a standard. The M proteins were identified by Ouchterlony agar 
diffusion tests using specific antisera from the National Communicable 
Disease Center. M4 and M29 were obtained from Dr. Lange (Loyola Univer-
sity, Maywood, Ill.). These proteins were prepared and purified 
according to Lange (19) and Lancefield (16). 
Group A polysaccharide. The group specific polysaccharide 
(APS) from group A beta hemolytic streptococci type 12 was obtained at 
Abbott Laboratories. The method of isolation and purification was 
essentially that of Fuller (9), and modified by Zittle and Harris 
(29). The exact procedure used was as follows: The streptococci were 
grown in a twenty liter carboy containing fourteen liters Todd-Hewitt 
broth plus two liters of a glucose-salts mixture (11). The medium 
was inoculated with 80 ml of a 24 hr inoculum and incubated at 37 C 
for 18 hr at which time 160 ml phenol was added to inactivate the 
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organisms. The streptococcal·cells were collected by centrifugation at 
4 4 x 10 x g in a Beckman zonal ultracentrifuge B XVI rotor with a 
continuous flow apparatus. The cells were then washed 4 times with 
10 times volume 0.01 M phosphate buffered saline pH 7.0 in a Sorvall 
3 RC-2B with the GSA rotor at 5 x 10 x g for 30 min. a 25% suspension 
of whole streptococcal cells was adjusted to pH 2.0 with 1.5 N HCl and 
was magnetically stirred while heating in a boiling water bath at 
90-95 C for 10 min. which removed the M protein associated with the 
cell wall. Following acid hydrolysis the suspension was rapidly cooled 
to 24 C in an ice bath and the pH was adjusted to neutrality with 1.5 N 
NaOH. The acid extracted cells are pelleted by centrifugation at 
1.6 x 104 x g for 30 min, resuspended to a 25% suspension in the phos-
phate buffered saline, and acid extracted a second time as above. The 
2X acid extracted cells were washed twicebycentrifugation using 
ten times the packed cell volume of 0.3 M sodium phosphate buffer pH 8.0 
then suspended to 20% in the same buffer containing 0.01% trypsin 
(Difeo Labs, Detroit, Mich.). Proteolysis was carried out at 37 C 
for 3 hr with magnetic stirring after which time the suspension was 
centrifuged, washed three times with 0.01 M phosphate buffered saline 
pH 7.0, suspended in water after the last wash, then lyophilized. 
Ten-fifteen grams of lyophilized material was added to 100 ml formamide 
(Mallinckrodt) preheated to 160 C. The suspension was magnetically 
stirring and maintained at temperature for 45 min. This treatment 
dissolved the polysaccharide (APS) from the acid extracted cells. APS 
being stable for approximately one hour under these conditions (9) allows 
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for good recoveries. The mixture was then cooled to 4 C and centrifuged 
at 2 x 104 x g for 16 hr and 250 ml 4 C acid alcohol(I:20 of 2.0 N HCl 
in anhydrous alcohol) added per 100 ml 4 C supernatant. Precipitation 
of impurities by the cold acid alcohol was allowed to proceed for 2 hr 
at 4 C before the residue was removed by centrifugation at 2 x 104 x g 
for 1 hr. The supernate was slowly added to an equal volume of 4 C 
acid acetone (1:20 of 2 N HCl and acetone) and the mixture was slowly 
stirred for 16 hr at 4 C during which time precipitation of APS was 
complete. The precipitate was centrifuged at 1.0 x 104 x g for 30 min 
recovered and lyophilized. Further purification of the APS was accom-
plished by taking 1.5-2 grams of dried material and twice extracting 
for APS, each time with 10 ml distilled water at 24 C for 15 min with 
magnetic stirring. The supernates were recovered by centrifugation at 
4 1.0 x 10 x g for 30 min pooled and maintained at 4 C while 5 volumes of 
cold acid acetone were slowly added for a second acetone precipitation. 
3 This mixture was held 16 hr at 4 C then centrifuged at 1.5 x 10 x g for 
30 min to collect the precipitate. Water and acetone were removed 
from the precipitate by suspending it in absolute ethyl alcohol. 
The precipitate became brittle and was easily powdered in absolute 
alcohol (29). The alcohol was removed by centrifugation and the pellet 
was suspended in anhydrous ethyl ether for complete drying. The APS 
powder was washeJ several times on a time scintered glass funnel with 
ether. At this time the weight of the crude APS was determined. One 
final purification step was undertaken by dissolving the APS in distilled 
water to a concentration of 60 mg/ml and ammonium sulfate added to 100% 
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saturation. This solution was. incubated at 4 C for 16 hr for maximum 
precipitation and then centrifuged at 1.0 x 105 x g for 1 hr. The 
pellet which consists of impurities was discarded and the supernate 
dialysed against distilled water until no ammonium sulfate was detected 
in the dialysate by barium chloride. The dialysed material was then 
concentrated to its pre-ammonium sulfate volume and precipitated with 
5 volumes cold acid acetone as previously described followed by the 
drying procedure. When the APS powder was recovered from the ether 
wash, it was air dried and stored at room temperature. 
Methylpentose determination. This assay was performed according 
to the method of Kabat (14) and L-rhamnose was used as the standard 
methylpentose. In a series of tubes 4.5 ml 4 C sulfuric acid solution 
(6 parts concentrated H2so4 plus 1 part distilled H20) was slowly 
added to each 1 ml of standard, blank or sample, all in duplicate. 
The tubes containing these solutions were then placed in a boiling 
water bath for 3 min cooled to 24 C in a room temperature water bath 
and 0.1 ml 3%cysteinehydrochloride was then stirred into each solution. 
After a 2 hr incubation period the optical density at A396 and A430 was 
determined for each sample in a Zeiss spectrophotometer. 
Biuret assay. This assay was performed according to the method 
of Kabat (14). Bovine serum albumin (Armour Pharm. Co. Fraction V, 
Chicago, Ill.) at a concentration of 1 mg/ml saline was used as the 
standard for this assay. Biuret reagent, 1.5 ml, was added to each 1 ml 
of standard, blank or sample in duplicate. Solutions were mixed and 
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incubated at 37.C for 30 min then read at A540 in a Zeiss spectrophoto-
meter. 
A lkaZine treatment of APS. Equal volumes of 1 mg/ml APS in saline 
and 0.2 M ammediol buffer pH 8.0 (2-amino-2-methyl-1,3-propanediol + HCl) 
were mixed then incubated 21 hr in a 37 C water bath. The mixture was 
cooled to 24 C then used to coat stabilized human erythrocytes (18). 
Esterification of APS. APS was converted to the 0-stearoyl de-
rivative by the procedure of Hannnerling and Westphal (10). Fifty mg 
of APS were dried in an evacuated ampoule at 40 C for 3 hr then dis-
solved in 4 ml anhydrous dimethyl formamide at 50 C. A solution of 
10 mg stearoyl chloride and 0.6 ml anhydrous pyridine dissolved in 0.1 
ml dimethyl formamide was added to the APS solution. The ampoule was 
sealed with a small stirrer inside and the reaction mixture was 
magnetically stirred at 24 C for 3 days. The reaction mixture, after 
opening the tube, was diluted with 0.5 ml water and poured into 25 ml 
alcohol and allowed to precipitate for 3 hr at 4 C. The precipitate 
was collected by centrifugation, washed with alcohol and dissolved in 
5 ml water. The esterified APS solution was filtered over a Sephadex 
G-25 column and lyophilized. This APS preparation was used to coat 
stabilized human erythrocytes. 
Conjugation of APS to human gamma globulin. The procedure for 
coupling APS to human gamma globulin (HGG) was performed according to 
the method Cuatrecasas (4) employed to couple amino group containing 
ligands to agarose. The following procedure was performed in a well 
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ventilated hood. Thirty mg APS/2.4 ml 0.1 M NaHC03 pH 8.3 was adjusted 
to pH 11.0 by adding microliter amounts of 1.0 N NaOH while the APS 
solution was magnetically stirred in a 16-20 C ice-water bath. Thirty 
mg cyanogen bromide (Aldrich Chem Co., Inc. Cat. # C9149-2 Milw., 
Wisc.) was added per 1.2 ml distilled water and the pH was maintained 
at 11.0 by addition of 1.0 N NaOH for about 12 min. As the reaction 
progressed, less NaOH was required to maintain pH 11.0 since proton 
release diminished as the reaction neared completion, at which time 
proton release ceased. Immediately, ice was added to the water bath 
lowering the temperature to 0-4 C and the pH was rapidly adjusted to 
10.0 with 1.0 N HCl. Immediately, 60 mg HGG/3 ml saline was added 
and the pH adjusted to 9.0 with 1.0 N HCl. These procedures had to be 
performed rapidly since the cyanogen bromide activated APS was unstable. 
The mixture was magnetically stirred 20 hr at 4 C then dialysed against 
0.01 M phosphate buffered saline pH 7.0. The resulting conjugate of 
APS and HGG is referred to as APS-HGG. 
Coating FPHE with M-proteins, APS, APS-HGG conjugate and HGG. 
Adsorbtion of antigens onto FPHE 0 was performed according to the 
method of Hirata (12). An optimal concentration of antigen was magnetic 
stirred at 24 C with a 1% suspension of FPHE in buffers of varying pH 
value for an optimal length of time. Following this coating reaction 
the erythrocytes were washed five times by centrifugation with ten 
times the erythrocyte volume of 0.11 M phosphate buffer pH 7.2. Each 
antigen coated erythrocyte preparation was then tested for its passive 
hemagglutination ability against specific rabbit antiserum and normal 
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rabbit serum. The set of coating conditions which yielded the highest 
titer against specific antiserum and lowest titer against normal 
serum were accepted as the optimum coating conditions for the antigen, 
provided the coated erythrocyte preparation showed no agglutination in 
the control wells containing serum diluent and cells. 
Serum dilutions. Serial two-fold dilutions were made in dispos-
able glass test tubes. Each dilution (1:8 to 1:524288) was made with 
a clean pipette and then stored at -20 C until further use. Diluent for 
these dilutions were 0.11 M phosphate buffer pH 7.2. 
HemaggZutination microtiter plates. Plastic microtiter trays 
with 96 "V" bottom wells were used (Linbro Chem. Co., Cat. ti IS-MVC-96, 
disposable, processed, New Haven, Conn.). 
HemaggZutination and passive hemaggZutination procedure. The 
0.1% gelatin-phosphate buffer solution was made by adding gelatin 
(Bacto gelatin Cat. /10143-02, Difeo Labs. Detroit, Mich.) to 0.11 M 
phosphate buffer pH 7.2 and heating at 40 C until the gelatin dissolved. 
The solution was cooled to 4 C in an ice bath and used as the diluent 
for a 0.25% erythrocyte suspension. Disposable pasteur pipettes 
(Scientific products, Cat. t!P5205) were employed to dispense 25 µl 
of the 0.25% erythrocyte suspension to 25 µl of serial two-fold dilutions 
of serum. Each serum sample was titered in duplicate. An erythrocyte 
control consisting of 25 µl.0.25% erythrocyte suspension added to 25 µl 
phosphate buffer was performed for each serum sample titered. The 
filled microtiter plates were then vigorously shaken on a vortex 
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mixer for 20 seconds, covered,. and incubated at 24 C for 18 to 20 hr 
at which time the titers were determined. Titers were most easily 
read by covering the microtiter plate with a folded piece of onionskin 
typing paper and placing the covered plate on a microtiter reading 
mirror (Linbro Chem. Co., New Haven Conn.). The plate was illuminated 
from above by fluorescent lighting at about six inches from the plate. 
The titer of a serum was determined as the highest serum dilution which 
differed from the erythrocyte control. 
Inhibition of passive hemaggZutination. In glass test tubes, 
one volume of inhibitor was added to an equal volume of serum. The 
mixture was briefly vortexed then incubated at 37 C for 1 hr followed 
by a 10 min incubation period at 4 C. Serial two-fold dilutions of the 
mixture were made and passive hemagglutination was performed in micro-
titer plates. 
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III. RESULTS 
A set of optimum coating conditions was determined for each anti-
gen adsorbed onto FPHE. These conditions are defined by the following 
parameters: the optimal concentration of antigen, optimal pH at which 
the coating reaction is run and the reaction time. Table I shows the 
optimum conditions for adsorbtion of the M-proteins onto FPHE. 
TABLE I 
COATING CONDITIONS FOR M-PROTEINS 
M-PROTEIN M-PROTEIN CONCENTRATION pH REACTION TIME 
Ml 10 µg/ml 1% FPHE 4.0 60 min. 
M3 10 µg/ml 1% FPHE 4.0 30 min. 
M4 2 µg/ml 1% FPHE 4.0 lS min. 
MS 10 µg/ml 1% FPHE 4.0 30 min. 
M6 10 µg/ml 1% FPHE 4.0 30 min. 
Ml2 10 µg/ml 1% FPHE 4.0 30 min. 
Ml4 10 µg/ml 1% FPHE 4.0 30 min. 
M29 so µg/ml 1% FPHE 4.0 60 min. 
M3, MS, M6, Ml2, and Ml4 protein have identical optimum coating condi-
tions whereas Ml, M4, and M29 deviate slightly from these conditions. 
The methylpentose assay performed on the group A polysaccharide 
demonstrated that the APS contains S9% rhamnose. This was in close 
agreement with the finding of Krause (lS) who demonstrated that the 
group A polysaccharide contains 60% wt/wt rhamnose. By biuret APS 
was shown to contain 2.S% protein. An attempt was made to adsorb the 
APS onto stabilized erythrocytes using the format established for pro-
teins. However the highest titer obtained for rabbit anti-APS was 1:64 
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and therefore a different approach for APS attachment to erythrocytes 
was sought. The method of Landy et al. (18) was employed by which the 
polysaccharide was first treated at alkaline pH prior to its adsorbtion 
onto FPHE. This procedure proved unfruitful for coating FPHE since 
non-specific agglutination of the coated erythrocytes was observed in 
the erythrocyte control wells. The procedure of Hammerling and West-
phal (10) was tried by which the polysaccharide is converted to its 
0-stearoyl derivative and then adsorbed to erythrocytes. Even though 
stabilized erythrocytes coated with this APS preparation gave a maximum 
antibody titer for rabbit anti-APS of 1:16384and 1:16 for normal rabbit 
serum, the antibody titers could not be diminished by first reacting 
APS with antiserum and then performing the passive hemagglutination 
assay on this mixture. Furthermore, of the fifty normal human sera 
tested with the esterified APS only one serum had a titer of 1:256 
and one serum a titer of 1:2048. The remaining 48 sera possessed titers 
512 or 1024. However when certain normal human sera were selected and 
reassayed at a later date the previous titers could not be duplicated 
even though a fresh preparation of esterified APS coated erythrocytes 
were used. Titers of selected normal human sera were also not inhibited 
by first incubating the sera with APS followed by passive hemagglutina-
tion assay on these mixtures. It wasn't until the method of Cuatrecasas 
(4) was employed .whereby the polysaccharide is first coupled to a protein 
and then absorbed to the stabilized erythrocytes that satisfactory results 
were obtained. For this study human gamma globulin was used as the pro-
tein to which group A polysaccharide was coupled. The optimum coating 
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conditions for the adsorbtion of the APS-HGG complex onto FPHE was 
determined as 5 µg APS-HGG/ ml 1% FPHE at pH 4.0 for 30 min. The APS-
HGG-FPHE preparation was satisfactory in the specific inhibition 
experiment and its passive hemagglutination results could be duplicated 
at a later date. Therefore this preparation was selected for deter-
mining APS antibody levels in all subsequent sera selected for this 
study. The sera were also tested with HGG adsorbed onto FPHE to 
ascertain that titers obtained with the APS-HGG-FPHE preparation were 
not due to any reaction between human serum and HGG. The optimum 
coating conditions established for adsorbing HGG onto FPHE were 10 µg 
HGG/ ml 1% FPHE at pH 4.0 for 10 min. Also HGG was incapable of inhi-
biting the reaction between normal human serum and the APS-HGG-FPHE 
preparation. 
Tables II through VII present all the hemagglutination data for 
all sera and antigens tested and Tables VIII through XVIII present 
the statistical summaries and significant data of the former tests. 
Tables IIA - IIF show the passive hemagglutination titers of 
normal human sera to M-proteins, APS, and HGG. Anti-M protein titers 
ranged from a low of <8 for Ml4 in sera #11 and #46 to a high of 
1:131072 for M3 in sera #1, 5, 17, 32, 33, 37, 42, 43, and 49. There-
fore a fifteen tube range in titer was observed between the weakest 
and strongest reaction of normal sera to the M proteins. 
The observation that normal human sera #11 and #46 lack detectable 
antibody to type Ml4 protein (Tables IIB and IIF) indicates that at 
least in these two normal sera type specific antibodies to the other 
r 
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M-proteins do not cross react.with Ml4. These tables also show 
that these two sera possess substantially lower titers to Ml (Sl2 and 
2S6) and MS (8 and 32) compared to the geometric mean titer of all 
normal sera for these proteins (3822 for Ml and SS2 for MS) even though 
their remaining M protein titers are comparable to the geometric mean 
titer for these proteins (Table XV). This is evidence that type speci-
fic antibody to Ml4 may enhance titers to Ml and MS. Further evidence 
for this enhancement is depicted by normal serum #31 (Table IID) which 
possesses lower than average titers to Ml4 (128), MS (96), and Ml 
(1024). In addition, normal serum #3S (Table IID) which possesses 
the highest titer of normal sera to Ml4 (4096) also has the highest 
MS (4096) and Ml (16384) titer of the normal sera tested. 
If a titer of 1:16384 can be assumed to represent a long lasting 
significant antibody level then only antibody to Ml, M3, M4, M6, and 
Ml2 appear to produce this effect. The highest titer detected in all 
normal sera to MS, Ml4 and M29 was 1:2048 with serum #3S the only 
exception. This serum possessed a titer of 1:4096 to MS and Ml4. 
The results obtained by reacting normal sera with APS-HGG-FPHE 
indicate that the majority of normal sera display a lower titer to 
APS than to all the M proteins with which they have been tested. This 
finding is verified by the geometric mean titer calculated for normal 
human sera versus APS. From Table XV it was seen that APS manifests 
a geometric mean of 329 compared to a geometric mean titer of SS2 for 
MS protein which yields the lowest mean titer of the M proteins in 
normal sera. There are however marked exceptions when individual sera 
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are observed, such as sera #11, 31, and 46 each of which displayed a 
substantially higher anti APS titer than either anti MS or Ml4 titers. 
Because HGG was used as the protein carrier through which APS 
was attached to erythrocytes it was necessary to test all sera with 
HGG-FPHE to ascertain whether titers to APS-HGG-FPHE were due to any 
cross reactivity between human serum and HGG. The finding that nearly 
all normal sera possess titers of <8 to HGG-FPHE indicates that in 
these normal sera HGG does not cross react or interfere with the 
passive hemagglutination assay for anti-APS antibody. However, sera 
#16, 24, and 43 each possess a titer of 1:8 with HGG-FPHE and serum 
#18 a titer of 1:32. These reactions with HGG-FPHE cannot account 
for the anti-APS titers in these same sera (1:512 for sera #16, 24, 
43 and 1:256 for serum #18) because the anti HGG agglutinins would 
be absent from these sera at the higher dilutions which were still 
capable of agglutinating the APS-HGG-FPHE erythrocyte preparation. 
Furthermore, the titers of 1:32 and 1:8 for HGG-FPHE in sera #18 and 
#24 respectively are probably a result of these sera reacting with 
uncoated FPHE rather than the HGG adsorbed onto the FPHE. This is 
shown in Table IIIB which indicates that sera #18 and #24 have titers 
to FPHE of 1:32 and 1:8 respectively. 
Tables IIIA - IIIE show the hemagglutination titers of normal 
human sera to stabilized erythrocytes. No detectable antibody (titer 
<8) was observed in 90%, 82%, 20%, and 36% of the normal sera to FPHE 
0-, FPTE, FPGE, and FPBE respectively. The highest titer (1:4096) was 
obtained to FPRE in sera #5, 8, 10, 23, 24, 27 and to FPPE in serum 
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#S. Therefore a ten tube range in titer was observed between the 
weakest and strongest reaction of normal sera to the stabilized ery-
throcytes. These tables further show that all normal sera tested 
agglutinate the stabilized erythrocytes of porcine, rabbit, duck, 
and dog at 2:_ 1:128 dilution of serum. Most sera also agglutinate 
rat, guinea pig and horse erythrocytes to this same level. Only a 
few sera agglutinate sheep, baby chick, and chicken erythrocytes at 
this level and no normal sera tested agglutinate the erythrocytes of 
human, turtle, or bovine when diluted 1:128. It should be noted that 
4 of SO normal sera (#9, 23, 24, 49) manifested a minimum titer of 
1:8 with FPHE and only 1 of the SO (serum #18) showed a titer as high 
as 1:24. It was essential that such low titers were obtained with 
FPHE since it was the erythrocyte to which the M proteins, APS, and 
HGG were coated. 
Table IV shows the passive hemagglutination titers of pharyngitis 
sera to M-proteins, APS, and HGG. Anti-M protein titers ranged from 
a low 1:8 for MS and Ml4 in serum #6 to a high of 1:6SS36 for M3 in 
sera #S, 7, 9, and 10. Therefore a thirteen tube range in titer was 
observed between the weakest and strongest reaction of pharyngitis 
sera to the M proteins. 
Evidence was present from Tables IIA-IIF that type specific 
antibody to Ml4 may enhance titers to Ml and MS. This correlation can 
partially be substantiated in sera from pharyntitis patients. Patients 
#6, 7, 8 (Table IV) collectively had the lowest Ml4, MS, and Ml titers 
of the pharyngitis group. However, in contrast to the finding in 
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normal sera, pharyngitis pati~nts #1 and #2 who possessed the highest 
Ml4 and MS titer in the pharyngitis group did not possess the highest 
Ml titer of their group. Sera #1 and #2 did however show an elevated 
anti-Ml titer. 
The most obvious difference between normal serum and pharyngitis 
serum was seen in their respective anti-APS titers. Tables IV and 
XVI show an anti-APS titer range of 1:1S36 to 1:8192 with a geometric 
mean titer of 3141 for pharyngitis sera whereas Tables II and XV 
depicts a range of 1:32 to 1:2048 with a geometric mean titer of only 
329 for normal sera. The pharyngitis serum group possessed a ten fold 
higher geometric mean antiAPS titer than the normal serum group. 
Furthermore the minimum anti-APS titer observed for a pharyngitis 
serum was nearly SO times higher than the minimum titer obtained in 
normal serum. 
As was observed for normal sera, the anti APS titers of pharyngitis 
sera were not a result of serum reacting with the HGG portion of the 
APS-HGG-FPHE preparation since the highest titer of pharyngitis serum 
to HGG-FPHE was 1:32 and the lowest titer to APS-HGG-FPHE was 1:1024. 
The titers of pharyngitis sera to HGG-FPHE were however significantly 
higher than those seen in normal sera to the same antigen. Even though 
the range in titers (<8 to 32) was the same in both pharyngitis and 
normal sera groups, pharyngitis sera possessed a geometric mean titer 
to HGG-FPHE of 10 compared to <8 for the geometric mean titer of normal 
sera (Tables XV and XVI). This reaction in pharyngitis serum cannot 
be accounted for by the reaction to uncoated FPHE since from Table XVI 
it was shown that FPHE possessed a geometric mean titer of <8 in 
pharyngitis sera. 
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Table V shows the hemagglutination titers of pharyngitis sera 
to stabilized erythrocytes. No detectable antibody titer (titer <8) 
was observed in 60% and 80% of the pharyngitis sera to FPHE 0 and 
FPTE respectively. The highest titer (1:2048) was obtained to FPRE 
in sera #3, 4, 6, 10 and in all ten pharyngitis sera to FPDoE. There-
fore a nine tube range in titer was observed between the weakest and 
strongest reaction of pharyngitis sera to the stabilized erythrocytes. 
It should be recalled that some of the normal sera tested lacked 
detectable agglutination titers to FPGE and FPBE. This was not the 
case in the pharyngitis serum group, as each serum in this group showed 
some detectable reaction to both FPGE and FPBE. 
Tables VIA - VIP show the passive hemagglutination titers of 
rheumatic heart sera to M-proteins, APS and HGG. Anti-M protein 
titers ranged from a low of 1:64 for Ml4 in patient #8 and #29 to a 
high of 1:262,144 for M3 in patient #24 serum #139. Therefore a 
twelve tube range in titer was observed between the weakest and strongest 
reaction of normal sera to the M proteins. Therefore in all three 
groups of sera (normal, pharyngitis, and rheumatic heart), Ml4 protein 
had the lowest titer and M3 manifested the highest titer of all M 
proteins tested. 
Previously it was mentioned that evidence existed whereby specific 
antibody to Ml4 may enhance titers to Ml and MS. The rheumatic heart 
group can partially substantiate this hypothesis. Patient #8 which 
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possessed the lowest Ml4 titer (Table VI F) also had the lowest MS 
and Ml titer of the rheumatic heart group. Patient #6 possessed 
the highest Ml4 and MS titer (Table VI D) but as in the pharyngitis 
group, not the highest titer to Ml although it was elevated. 
As was observed between the normal and pharyngitis groups, the 
anti-APS geometric mean titer (22S4) for the rheumatic heart group was 
substantially higher than that for the normal group (329) tables 
XV and XVII. However the range of antiAPS titers in the rheumatic 
heart group (1:64 to 1:8192) was not as varied from the normal group 
(1:32 to 1:2048) as the range in the pharyngitis group (1:1S36 to 1: 
8192) was from normal. 
The comparison pertaining to the antiHGG titers observed between 
the normal and pharyngitis groups was essentially the same as that 
between the rheumatic heart and normal groups. Even though the range 
in titers is essentially the same in both groups (<8 to 1:32 for 
normal .<8 to 1:64 for rheumatic heart - Tables XV and XVII), rheumatic 
heart sera possessed a geometric mean titer of 11 for HGG compared to 
<8 for the normal group. As was the case with the pharyngitis group, 
this reaction in rheumatic heart serum could not be accounted for by 
reaction to uncoated FPHE since from Table XVII it was shown that FPHE 
possessed a geometric mean titer of <8 in rheumatic heart serum. 
Tables VILA - VII N show the hemagglutination titers of rheumatic 
heart sera to stabilized erythrocytes. No detectable antibody (titer 
<8) was observed in at least one serum sample to the following stabilized 
erythrocytes: FPSE, FPHE 0-, FPTE, FPBCE, FPCE, FPGE, and FPBE. The 
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highest titer (1:4096) was obtained to FPPE, FPRE, and FPDoE. There-
fore a ten tube range in titer was observed between the weakest and 
strongest reaction of rheumatic heart sera to the stabilized erythro-
cytes. 
In order to evaluate whether any significant differences existed 
between mean titers, Duncan's multiple range test (5) was performed 
on the data. Each group of sera, normal, pharyngitis, and rheumatic 
heart was analysed individually to determine whether the mean M protein 
titers differed significantly from each other. Table VIII shows the 
results of the range test when performed on the data obtained for normal 
sera tested with M-proteins. With the exception of Ml4 and M29, all 
M proteins manifest significantly different_mean titers in the normal 
serum group. Contrary to this observation, Table IX shows that the 
pharyngitis serum group did not possess any mean M protein titer which 
was significantly different from all the other mean protein titers. 
Each mean M protein titer could not be distinguished from at least 
one other mean M protein titer. The rheumatic heart group, as shown 
in Table X did not distinguish between the mean titer of Ml and M4, 
nor between M6 and Ml2, however the remaining mean M protein titers were 
denoted as being significantly different from all other mean M protein 
titers. 
The Duncan's multiple range test was also performed on the erythro-
cyte titer data from the three groups of sera. Tables XI through XIII 
illustrate that each of the three groups of sera demonstrate significantly 
different titers between many of the erythrocytes tested. A few specific 
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observations from these tables are the following. Titers obtained 
in normal and pharyngitis sera to FPHE and FPTE were not significantly 
different whereas the same erythrocytes demonstrate significantly 
different titers in rheumatic heart sera. FPBE manifests significantly 
different titers from all other erythrocyte titers in each of the three 
groups of sera. Titers of FPCE and FPBCE were not significantly 
different from each other in each of the three sets of sera. FPPE 
mean titer was significantly different from all other erythrocytes 
only in normal sera. Whether such observations are peculiar for these 
particular populations alone or whether these phenomena are character-
istic of all rheumatic heart, pharyngitis, and normal populations 
remains speculative until many more individuals are tested. 
Differences between the three populations can be demonstrated 
by comparison of the individual M protein and APS titers obtained for 
each member of a group as depicted in Table XIV. In each comparison 
a higher percentage of rheumatic heart patients possessed titers 
greater than or equal to a selected high titer. A comparison of normal 
sera to pharyngitis sera showed that a greater percentage of pharyngitis 
patients possessed high titers to APS, Ml, and M6, but that a greater 
percentage of normal sera had high titers to M3 and M4. It should 
be noted that selection of rheumatic heart serum information for this 
comparison was performed by denoting a patient as positive if even one 
of his serum sample titers was greater than or equal to the selected 
high titer. This procedure was selected because the geometric mean 
titers of each individual rheumatic heart patient would not devulge 
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the magnitude of their reaction to these antigens throughout the dura-
tion of their illness. 
Table XIV also shows a comparison of the erythrocyte reactions 
for the three groups of sera by indicating the percentage of each 
group that exceeds or equals a selected high titer. When M-proteins 
were compared in this fashion it was seen that for every M-protein 
a higher percentage of rheumatic heart patients possessed titers equal 
to or in excess of the selected high titer. However, when the erythro-
cyte reactions were observed it could be seen that a greater percentage 
of pharyngitis patients had titers exceeding or equal to the selected 
high titer for horse, goat, dog, and sheep erythrocytes. The remaining 
erythrocytes however did manifest high titers in a greater percentage 
of the rheumatic heart patients. A greater percentage of normal sera 
than pharyngitis sera possessed high titers to erythrocytes of rabbit, 
guinea pig, and porcine; but in every case a higher percentage of 
rheumatic heart patients possessed high titers to the other erythrocytes 
compared to normal sera. 
Tables XV, XVI, and XVIII present statistical information on 
the three sets of sera. The geometric mean titer along with the 
standard deviation, variance, and standard error of the mean for each 
titer are shown for each of the antigens with which the three groups 
of sera were tit~red. This information was used to prepare the Duncan's 
multiple range and T-test analyses. Also shown in these tables are 
the minimum and maximum titers obtained for each serum group by each 
antigen. If one considers a four fold increase or decrease in titer 
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as a significant difference between any two titers, then the following 
differences can be noted. APS was the only streptococcal antigen 
tested which showed a significantly higher maximum titer in the disease 
serum compared to normal serum. The highest anti-APS titer in normal 
serum was 1:2048 in one of fifty sera whereas one of ten pharyngitis 
and 4 of thirty rheumatic heart patients manifested titers to APS 
as high as 1:8192. When the stabilized erythrocytes were compared it 
was noted that FPTE and FPCE were the only erythrocytes which showed 
a maximum titer difference between the groups of sera. One rheumatic 
heart serum had a titer of 1:64 to FPTE whereas the highest titer in 
normal and pharyngitis sera to this erythrocyte was 1:16. Likewise, 
two rheumatic heart sera had titers of 1:512 to FPCE whereas the highest 
titer in normal and pharyngitis sera to FPCE was 1:128. 
The geometric mean titers of rheumatic heart, pharyngitis, and 
normal sera were used to show by means of the T-test whether or not 
there were significant differences between the three sets of sera. The 
data in Table XVIII showed that except for Ml and Ml2 there was a 
significant difference at the 1% level for the geometric mean titers 
of each M protein and APS between normal and pharyngitis sera. This 
comparison revealed that normal serum and pharyngitis serum could not 
be distinguished by their Ml and Ml2 antibody titers. Normal sera 
possessed higher 0 antibody titers than pharyngitis sera to M3, M4, MS, 
Ml4 and M29 proteins, but pharyngitis sera manifested a higher than 
normal antibody titer to APS. 
A comparison between rheumatic heart and normal sera was also 
/ 
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shown in Table XVIII. Except.for M3 which manifested a higher titer 
in normal sera and M4 which was not significantly different between 
these two groups, the M proteins and APS showed significantly higher 
titers in sera from rheumatic heart patients than in normal sera. 
From this table it can also be seen that of the streptococcal antigens 
tested, only M3 manifested a significantly higher titer in normal 
sera than in either pharyngitis or rheumatic heart sera. 
Comparisons between the pharyngitis and rheumatic heart group 
can also be made from Table XVIII. Titers to the group A polysaccharide 
were not significantly different between these two sets of sera. 
Of the M-proteins, only M3 and M6 failed to show significantly different 
mean antibody titers between these two groups of sera. 
T-tests were performed on the geometric mean titers obtained 
for erythrocyte reactions in the three groups of sera (Table XVIII). 
Most erythrocytes manifested geometric mean titers for normal sera 
which were significantly different from both rheumatic heart and pharyn-
gitis sera. The two exceptions were that the geometric mean titers 
for guinea pig and rabbit erythrocytes in normal sera were not signi-
ficantly different from those in pharyngitis sera. Furthermore 
rheumatic heart sera was differentiated from pharyngitis sera be a 
significant difference between these two groups in their reaction with 
erythrocytes of human, rat, horse, dog, and goat. In each case 
pharyngitis serum possessed the higher geometric mean titer of the two. 
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TABLE II A 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS, AND HGG 
AG NHS/11 2 3 4 5 6 7 8 9 
Ml 8192 8192 1024 2048 8192 8192 1024 4096 8192 
8192 8192 1024 2048 8192 8192 1024 4096 8192 
M3 131072 16384 32768 65536 131072 65536 65536 32768 32768 
131072 16384 32768 65536 131072 65536 65536 32768 32768 
M4 8192 16384 16384 16384 16384 16384 16384 16384 32768 
8192 16384 16384 16384 8192 16384 16384 16384 32768 
MS 512 1024 512 1024 1024 512 256 1024 512 
512 1024 1024 1024 1024 1024 256 1024 512 
M6 8192 16384 8192 16384 16384 16384 8192 32768 8192 
8192 16384 8192 16384 16384 16384 8192 32768 8192 
Ml2 8192 16384 16384 32768 16384 32768 16384 16384 16384 
8192 16384 16384 32768 16384 32768 16384 16384 16384 
Ml4 1024 2048 512 2048 2048 2048 1024 512 1024 
1024 1024 512 2048 2048 2048 1024 512 1024 
M29 512 1024 1024 1024 1024 512 1024 1024 1024 
512 1024 1024 1024 1024 512 1024 1024 1024 
APS 512 256 128 512 2048 256 256 2048 1024 
256 256 128 512 2048 256 256 1024 512 
HGG <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
---
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TABLE II B 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS AND HGG 
AG NHS/110 11 12 13 14 15 16 17 18 
Ml 2048 512 8192 8192 2048 2048 8192 8192 8192 
2048 512 8192 8192 2048 2048 8192 8192 8192 
M3 65536 65536 65536 65536 65536 16384 32768 131072 32768 
65536 65536 65536 65536 65536 16384 32768 131072 32768 
M4 16384 16384 16384 8192 32768 8192 8192 8192 8192 
16384 16384 16384 8192 32768 8192 8192 8192 8192 
. 
M5 256 8 2048 256 1024 1024 1024 256 256 
256 8 2048 512 1024 1024 1024 256 256 
M6 4096 8192 16384 16384 8192 8192 16384 8192 4096 
8192 8192 16384 16384 8192 8192 16384 8192 4096 
Ml2 16384 16384 16384 16384 16384 16384 32768 16384 8192 
16384 16384 16384 16384 16384 16384 32768 16384 16384 
Ml4 1024 <8 2048 1024 1024 2048 2048 1024 512 
1024 <8 4096 1024 1024 2048 2048 1024 1024 
M29 512 512 2048 1024 1024 1024 1024 512 512 
512 512 2048 1024 1024 1024 1024 512 512 
APS 512 256 512 512 256 256 512 512 256 
512 256 512 512 256 256 512 512 256 
HGG <8 <8 <8 <8 <8 <8 8 <8 32 
<8 <8 <8 <8 <8 <8 8 <8 32 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
37. 
TABLE II C 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS, AND HGG 
AG NHSll19 20 21 22 23 24 25 26 27 
Ml 2048 2096 8192 8192 1024 8192 8192 2048 16384 
2048 4096 8192 8192 1024 8192 8192 2048 16384 
M3 8192 32768 65536 65536 65536 65536 32768 65536 65536 
8192 32768 65536 65536 65536 65536 32768 65536 65536 
M4 2048 16384 16384 16384 16384 8192 16384 32768 16384 
4096 16384 16384 16384 16384 8192 16384 32768 16384 
MS 512 1024 512 1024 1024 1024 512 256 1024 
512 1024 512 1024 1024 1024 512 256 1024 
M6 1024 4096 4096 16284 16384 4096 16384 8192 4096 
1024 4096 4096 16384 16384 4096 16384 8192 4096 
Ml2 8192 8192 32768 16384 32768 16384 16384 16384 16384 
16384 16384 32768 16384 32768 16384 16384 16384 16384 
Ml4 512 2048 2048 2048 512 2048 2048 512 2048 
1024 2048 2048 2048 512 2048 2048 512 2048 
M29 512 1024 512 1024 2048 1024 512 512 512 
1024 1024 512 1024 4096 1024 512 512 512 
APS 256 256 512 64 512 512 512 256 64 
512 256 512 64 512 512 1024 256 128 
HGG <8 8 <8 <8 <8 8 <8 <8 <8 
<8 <8 <8 <8 <8 8 <8 <8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
38. 
TABLE II D 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS, AND HGG 
AG NHS/128 29 30 31 32 33 34 35 36 
Ml 2048 4096 8192 1024 8192 4096 1024 16384 8192 
2048 4096 8192 1024 8192 4096 1024 16384 8192 
M3 65536 16384 65536 65536 131072 131072 65536 65536 65536 
65536 16384 65536 65536 131072 131072 65536 65536 65536 
M4 16384 16384 8192 8192 8192 16384 8192 16384 8192 
16384 8192 8192 8192 16384 16384 8192 32768 8192 
M5 512 1024 1024 64 1024 512 256 4096 512 
512 1024 1024 128 1024 512 256 4096 512 
M6 16384 8192 8192 8192 8192 8192 4096 8192 4096 
16384 8192 8192 8192 8192 8192 4096 8192 4096 
Ml2 16384 8192 8192 16384 16384 32768 16384 16384 32768 
16384 16384 8192 16384 16384 32768 16384 16384 32768 
Ml4 1024 1024 1024 128 1024 2048 512 4096 2048 
1024 1024 1024 128 2048 2048 512 4096 2048 
M29 1024 2048 1024 512 1024 512 512 2048 1024 
1024 2048 1024 512 1024 1024 512 2048 1024 
APS 32 128 1024 512 256 256 512 512 512 
32 128 1024 512 256 256 512 512 512 
HGG <8 <8 8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
39. 
TABLE II E 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS, AND HGG 
AG NHSlt37 38 39 40 41 42 43 44 45 
Ml 8192 8192 8192 2048 512 8192 1024 2048 4096 
8192 8192 8192 2048 512 8192 1024 2048 4096 
M3 131072 32768 65536 65536 65536 131072 131072 65536 8192 
131072 32768 65536 65536 65536 131072 131072 65536 8192 
M4 4096 8192 8192 16384 16384 16384 16384 16384 4096 
8192 8192 8192 32768 16384 16384 16384 32768 4096 
MS 1024 2048 512 2048 512 1024 512 256 256 
1024 2048 512 2048 512 1024 512 256 512 
M6 8192 32768 8192 16384 8192 8192 8192 2048 1024 
8192 32768 8192 16384 8192 8192 8192 2048 2048 
Ml2 32768 16384 8192 32768 8192 32768 16384 16384 16384 
32768 16384 16384 32768 8192 32768 16384 16384 16384 
Ml4 512 1024 1024 2048 256 1024 1024 512 512 
512 1024 1024 2048 512 1024 1024 1024 512 
M29 512 1024 512 512 512 1024 1024 512 1024 
512 1024 512 1024 1024 1024 1024 512 1024 
APS. 256 1024 256 128 1024 256 512 256 256 
256 1024 256 128 1024 256 512 256 256 
HGG <8 <8 <8 <8 <8 <8 8 <8 <8 
<8 <8 <8 <8 <8 <8 8 <8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
40. 
TABLE II F 
PASSIVE HA TITERS OF NORMAL HUMAN SERA TO M-PROTEINS, APS, AND HGG 
AG NHSl/46 47 48 49 50 
/ 
Ml 256 8192 1024 8192 2048 
256 8192 1024 8192 2048 
M3 65536 32768 65536 131072 65536 
65536 32768 65536 131072 65536 
M4 16384 16384 8192 16384 8192 
16384 16384 8192 16384 8192 
M5 32 1024 512 256 128 
32 2048 512 256 128 
M6 8192 8192 4096 4096 4096 
8192 8192 4096 4096 4096 
Ml2 8192 16384 16384 16384 16384 
8192 16384 16384 16384 16384 
Ml4 <8 2048 1024 512 1024 
<8 2048 1024 512 1024 
M29 1024 2048 512 512 256 
1024 2048 1024 512 256 
APS 256 215 128 128 64 
256 512 128 256 64 
HGG <8 <8 <8 <8 <8 
<8 <8 <8 <8 8 
--
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Abbreviations used to denote double aldehyde stabilized erythrocytes are 
as follows: 
Erythrocyte Abbreviation 
Porcine FPPE 
Rabbit FPRE 
Sheep FPSE 
Human 0 FPHE 0 
Duck FPDuE 
Turtle FPTE 
Baby Chick FPBCE 
Chicken FPCE 
Rat FPRaE 
Guinea Pig FPGPE 
Horse FPHoE 
Dog FPDoE 
Goat FPGE 
Bovine FPBE 
42. 
TA,BLE III A 
HA TITERS OF NORMAL HUMAN SERA TO STABILIZED ERYTHROCYTES 
AG NHS/fl 2 3 4 5 6 7 8 
FPPE 512 2048 512 256 4096 1024 256 1024 
512 2048 512 256 4096 1024 256 1024 
FPRE 2048 2048 2048 1024 4096 2048 1024 4096 
2048 2048 2048 1024 4096 2048 1024 4096 
FPSE 32 64 32 32 256 32 16 16 
32 64 32 32 256 32 16 16 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 8 <8 <8 
FPDuE 128 256 128 128 512 128 512 512 
128 256 128 128 512 128 512 512 
FPTE <8 <8 <8 <8 8 16 <8 <8 
<8 <8 <8 <8 8 16 <8 <8 
FPBCE 32 64 32 32 256 64 64 16 
32 64 32 32 256 64 64 32 
FPCE <8 64 32 32 128 32 64 16 
8 64 32 32 128 64 64 16 
FPRaE 512 1024 512 64 1024 512 256 512 
512 1024 512 128 1024 512 256 512 
FPGPE 128 256 256 64 1024 512 64 256 
128 256 256 64 1024 512 128 512 
FPHoE 1024 512 1024 64 1024 512 256 64 
1024 512 1024 64 1024 512 256 64 
FPDoE 1024 2048 1024 1024 2048 1024 1024 1024 
1024 2048 1024 1024 2048 1024 1024 1024 
FPGE 32 32 16 <8 128 <8 16 8 
32 32 16 <8 128 <8 16 8 
FPBE 16 32 16 8 64 32 <8 16 
16 32 16 8 128 32 <8 16 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
43. 
TABLE III B 
HA TITERS OF NORMAL HUMAN SERA TO STABILIZED ERYTHROCYTES 
AG NHS/19 10 11 12 13 14 15 16 
FPPE 1024 1024 512 512 512 512 256 2048 
1024 1024 512 512 512 512 512 2048 
FPRE 2048 4096 2048 1024 1024 1024 512 2048 
4096 4096 2048 1024 1024 1024 512 2048 
FPSE 32 32 32 16 32 32 16 16 
32 64 32 16 32 32 16 32 
FPHE 8 <8 <8 <8 <8 <8 <8 <8 
8 <8 <8 <8 <8 8 <8 <8 
FPDuE 512 256 256 128 1024 512 128 1024 
512 256 256 128 1024 512 128 1024 
FPTE 8 <8 <8 <8 <8 <8 <8 <8 
8 <8 <8 <8 <8 <8 <8 <8 
FPBCE 64 64 64 32 64 64 32 16 
64 64 64 32 64 64 64 32 
FPCE 64 64 32 32 64 64 32 32 
128 64 32 32 64 64 32 32 
FPRaE 1024 1024 512 128 512 256 256 512 
1024 1024 512 128 512 256 256 512 
FPGPE 512 512 256 256 256 128 256 512 
512 512 256 256 256 128 256 512 
FPHoE 512 512 64 128 128 128 64 512 
512 512 64 128 128 128 64 512 
FPDoE 1024 2048 1024 512 1024 1024 1024 1024 
2048 2048 1024 1024 1024 1024 1024 1024 
FPGE 32 64 32 8 8 8 <8 8 
16 64 32 8 8 8 <8 <8 
FPBE 32 16 8 <8 8 <8 <8 16 
32 16 8 <8 8 <8 <8 16 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
44. 
TABLE III C 
HA TITERS OF NORMAL HUMAN SERA TO STABILIZED ERYTHROCYTES 
AG NHSl/17 18 19 20 21 22 23 24 
FPPE 1024 1024 256 1024 512 128 1024 2048 
2048 1024 256 1024 1024 256 1024 2048 
FPRE 2048 2048 1024 2048 2048 512 4096 4096 
2048 2048 1024 2048 2048 512 4096 4096 
FPSE 16 32 16 256 32 64 64 64 
16 32 16 256 32 64 64 64 
FPHE <8 16 <8 <8 <8 <8 8 8 
<8 32 <8 <8 <8 <8 8 8 
FPDuE 512 256 128 1024 512 128 512 512 
512 256 128 1024 512 128 512 512 
FPTE <8 8 <8 <8 8 <8 <8 8 
<8 8 <8 <8 8 <8 <8 8 
FPBCE 32 64 32 128 32 64 64 64 
32 64 32 128 32 64 64 64 
FPCE 32 32 32 128 32 32 32 64 
64 32 64 128 32 32 32 64 
FPRaE 512 512 128 512 512 64 512 1024 
512 512 128 512 512 128 512 1024 
FPGPE 512 256 64 512 256 64 256 512 
512 256 128 512 256 128 256 1024 
FPHoE 512 512 64 1024 128 32 64 1024 
512 512 64 1024 128 32 64 1024 
FPDoE 1024 1024 2048 1024 1024 1024 1024 2048 
1024 1024 2048 1024 1024 1024 2048 2048 
FPGE 16 8 16 128 64 16 128 128 
16 8 16 128 64 16 128 128 
FPBE 32 16 <8 16 16 <8 16 32 
32 16 <8 16 16 <8 16 32 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
r 
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TABLE III D 
HA TITERS OF NORMAL HUMAN SERA TO STABILIZED ERYTHROCYTES 
AG NHSll25 26 27 28 29 30 31 32 33 34 
FPPE 1024 1024 1024 256 128 2048 128 2048 512 512 
1024 1024 1024 256 128 2048 256 2048 512 512 
FPRE 1024 2048 4096 512 256 4096 1024 2048 2048 1024 
1024 4096 4096 512 256 2096 1024 2048 2048 1024 
FPSE 32 16 16 16 16 64 16 32 16 64 
32 32 16 16 32 64 16 32 16 64 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
FPDuE 128 128 256 128 256 256 256 512 256 128 
128 128 256 128 256 256 256 512 256 128 
FPTE <8 <8 <8 <8 <8 8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 8 <8 <8 <8 <8 
FPBCE 64 32 64 16 32 32 16 128 32 32 
64 32 64 16 32 32 16 128 32 32 
FPCE 32 8 32 16 32 32 8 128 32 64 
32 8 32 32 32 32 8 128 32 64 
FPRaE 256 512 512 128 64 512 128 512 256 128 
256 512 512 128 64 512 128 1024 256 128 
FPGPE 64 256 128 128 128 256 128 256 256 64 
64 256 128 128 128 256 128 256 256 64 
FPHoE 512 512 64 32 128 128 64 1024 64 64 
512 512 64 32 128 128 64 1024 64 64 
FPDoE 1024 1024 1024 1024 1024 1024 512 2048 1024 512 
1024 1024 1024 1024 1024 1024 512 2048 1024 512 
FPGE 16 <8 32 <8 8 64 32 16 . 8 32 
32 <8 32 <8 8 64 32 32 8 32 
FPBE 8 16 8 <8 <8 64 <8 16 8 <8 
8 16 8 <8 <8 64 <8 32 8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
46. 
TABLE III E 
HA TITERS OF NORMAL HUMAN SERA TO STABILIZED ERYTHROCYTES 
AG NHSlf 35 36 37 38 39 40 41 42 43 
FPPE 256 512 1024 1024 2048 512 512 256 256 
256 512 1024 2048 2048 512 512 512 256 
FPRE 1024 2048 2048 2048 1024 2048 1024 1024 512 
1024 2048 2048 2048 1024 2048 1024 1024 512 
FPSE 32 32 32 32 32 128 16 32 32 
32 32 32 32 32 128 32 32 32 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 
FPDuE 128 128 512 256 512 512 128 256 265 
128 182 512 256 512 512 128 256 256 
FPTE <8 <8 <8 <8 <8 8 <8 <8 <8 
<8 <8 <8 <8 <8 16 <8 <8 <8 
FPBCE 64 32 32 32 16 32 16 64 32 
64 32 32 32 16 32 16 128 64 
FPCE 32 16 16 32 64 32 32 64 64 
64 16 32 64 64 32 32 64 64 
FPRaE 256 256 512 512 512 128 256 128 64 
256 256 1024 512 512 128 256 128 64 
FPGPE 64 128 256 256 256 256 64 256 128 
64 128 256 256 256 256 64 256 128 
FPHoE 128 64 128 64 256 128 64 512 32 
128 64 128 128 256 128 64 512 32 
FPDoE 512 1024 1024 1024 1024 1024 1024 2048 1024 
512 1024 1024 1024 1024 1024 1024 2048 1024 
FPGE 32 16 <8 <8 8 64 8 <8 16 
32 16 <8 <8 8 64 8 <8 16 
FPBE <8 <8 32 16 16 <8 32 <8 <8 
<8 8 32 16 16 <8 32 <8 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
47. 
TABLE III F 
HA TITERS OF NORMAL HUMAN.SERA TO STABILIZED ERYTHROCYTES 
AG NHSl/44 45 46 47 48 49 50 
FPPE 1024 512 512 1024 512 128 128 
1024 512 512 1024 512 128 128 
FPRE 2048 1024 2048 1024 1024 512 256 
2048 1024 2048 1024 1024 1024 256 
FPSE 64 32 32 32 32 32 16 
128 32 32 32 32 32 32 
FPHE <8 <8 <8 <8 <8 8 <8 
<8 <8 <8 <8 <8 8 <8 
FPDuE 256 128 256 256 256 512 512 
256 128 256 256 256 512 512 
FPTE <8 <8 <8 8 <8 <8 <8 
<8 <8 <8 8 <8 <8 <8 
FPBCE 64 32 32 64 128 64 64 
64 32 32 64 128 64 64 
FPCE 32 32 32 64 128 64 128 
32 32 32 64 128 64 128 
FPRaE 512 256 512 128 512 128 256 
512 256 512 128 512 128 256 
FPGPE 256 128 256 512 128 64 128 
256 128 256 512 128 64 128 
FPHoE 128 2048 64 128 128 128 128 
128 2048 64 128 128 128 128 
FPDoE 1024 2048 1024 1024 1024 512 1024 
1024 2048 1024 1024 1024 512 1024 
FPGE 64 16 8 64 8 32 16 
64 16 <8 64 8 32 16 
FPBE 32 <8 8 <8 16 32 <8 
32 <8 16 <8 16 32 <8 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
48. 
TABLE IV 
PASSIVE HA TITERS OF PHARYNGITIS SERA TO M-PROTEINS, APS, AND HGG 
AG PS#l 2 3 4 5 6 7 8 9 10 
Ml 8192 8192 8192 16384 1024 1024 512 512 2048 32768 
8192 8192 16384 16384 2048 1024 512 512 2048 32768 
M3 32768 32768 32768 32768 65536 32768 65536 16384 65536 65536 
32768 32768 32768 32768 65536 32768 65536 16384 65536 65536 
M4 4096 4096 8192 8192 4096 4096 16384 4096 4096 8192 
4096 4096 16384 8192 4096 4096 16284 4096 4096 8192 
MS 1024 1024 512 512 128 8 8 32 256 128 
1024 1024 1024 512 128 8 16 64 512 128 
M6 32768 16384 32768 32768 16384 32768 16384 4096 32768 4096 
32768 16384 32768 32768 16384 32768 32768 4096 32768 4096 
Ml2 32768 16384 16384 32768 8192 16384 16384 16384 16384 16384 
32768 16384 16384 32768 8192 16384 16384 16384 16384 16384 
Ml4 2048 2048 1024 1024 128 8 32 64 1024 512 
2048 2048 2048 1024 128 8 32 64 1024 512 
M29 2048 1024 4096 512 512 256 256 512 512 512 
2048 1024 4096 1024 1024 512 256 256 512 512 
APS 4096 4096 8192 4096 2048 4096 2048 1024 2048 2048 
4096 4096 8192 4096 4096 4096 2048 2048 2048 2048 
HGG 32 <8 8 8 <8 <8 32 8 8 16 
32 <8 16 16 <8 <8 32 8 8 16 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
49 
TABLE V 
.HEMAGGLUTINATION TITERS OF PHARYNGITIS SERA TO 
STABILIZED ERYTHROCYTES 
AG PS/fl 2 3 4 5 6 7 8 9 10 
FPPE 1024 1024 1024 1024 512 1024 512 512 1024 1024 
1024 1024 1024 1024 512 1024 1024 512 1024 2048 
FPRE 1024 1024 2048 2048 1024 2048 512 1024 1024 2048 
1024 2048 2048 2048 1024 2048 512 1024 1024 2048 
FPSE 64 128 64 64 64 64 16 32 64 128 
64 128 64 64 64 64 16 32 64 128 
FPHE <8 8 <8 8 <8 8 8 <8 <8 <8 
<8 8 <8 8 <8 8 16 <8 <8 <8 
FPDuE 256 1024 256 256 128 256 256 512 256 1024 
512 1024 256 256 128 256 256 512 256 1024 
FPTE 16 <8 <8 <8 <8 <8 <8 <8 <8 8 
16 <8 <8 <8 <8 <8 <8 <8 <8 8 
FPBCE 64 64 64 64 32 64 64 64 46 64 
64 64 64 64 64 64 64 32 64 64 
FPCE 128 128 64 128 64 64 64 64 32 64 
128 128 64 128 64 64 64 128 32 64 
FPRaE 512 1024 1024 1024 256 512 256 256 512 1024 
512 1024 1024 1024 256 512 256 256 1024 1024 
FPGPE 256 256 256 512 128 128 128 256 64 256 
256 256 256 512 128 256 128 256 64 256 
FPHoE 1024 1024 1024 1024 1024 1024 64 512 1024 1024 
1024 1024 1024 1024 1024 1024 64 512 1024 1024 
FPDoE 2048 2048 2048 2048 2048 2048 2048 2048 2048 2048 
2048 2048 2048 2048 2048 2048 2048 2048 2048 2048 
FPGE 128 128 128 32 32 64 32 64 64 32 
128 128 128 32 32 128 32 64 64 32 
FPBE 8 32 32 32 32 32 16 16 16 128 
8 32 32 32 32 32 16 16 16 128 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI A 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient Ill 
AG RHStll 2 3 4 5 6 7 8 9 10 
Ml 8192 8192 8192 8192 8192 8192 8192 8192 8192 8192 
'8192 8192 8192 8192 8192 8192 8192 8192 8192 16384 
M3 65536 16384 32768 8192 16384 16384 65536 32768 131072 
65536 16384 32768 16384 16384 16384 65536 32768 131072 
M4 2048 16384 1024 2048 16384 16384 16384 
2048 16384 1024 2048 16384 16384 16384 
MS 2048 2048 2048 2048 
2048 2048 2048 2048 
M6 16384 16384 32768 8192 16384 16384 16384 8192 16384 16384 
16384 16384 32768 8192 16384 16384 16384 8192 16384 16384 
Ml2 16384 8192 32768 32768 16384 16384 8192 32768 32768 32768 
16384 8192 32768 32768 16384 16384 8192 32768 32768 32768 
Ml4 1024 1024 4096 1024 2048 2048 4096 4096 
1024 2048 4096 1024 2048 2048 4096 4096 
M29 2048 2048 2048 2048 
2048 2048 2048 2048 
APS 4096 4096 4096 2048 
4096 4096 4096 2048 
HGG 8 8 8 8 
8 8 8 16 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate 
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TABLE VI B 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 112 
AG RHSl!ll 12 13 14 15 16 17 18 
Ml 8192 8192 16384 16384 16384 16384 8192 16384 
8192 8192 16384 16384 16384 16384 16384 16384 
M3 65536 32768 32768 16384 32768 131072 32768 65536 
65536 32768 32768 16384 32768 131072 32768 65536 
M4 4096 2048 16384 16384 16384 
4096 2048 16384 16384 16384 
MS 512 512 512 
512 512 512 
M6 16384 32768 32768 32768 16384 32768 16384 16384 
16384 32768 32768 32768 16384 32768 16384 16384 
Ml2 16384 32768 65536 65536 16384 32768 32768 32768 
16384 32768 65536 65536 16384 65536 32768 65536 
Ml4 1024 1024 1024 2048 2048 2048 
1024 1024 1024 2048 2048 2048 
M29 1024 1024 1024 
1024 1024 1024 
APS 4096 4096 4096 
4096 4096 4096 
HGG 8 32 8 
8 32 16 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI C 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient t/3 
AG RHS/119 20 21 22 23 24 25 26 27 
Ml 8192 16384 8192 8192 16384 16384 16384 8192 16384 
8192 16384 16384 8192 16384 16384 16384 8192 16384 
M3 65536 32768 16384 8192 32768 65536 65536 131072 
65536 32768 16384 8192 65536 65536 65536 131072 
M4 2048 4096 4096 2048 16384 16384 16384 16384 
2048 8192 4096 2048 16384 16384 16384 16384 
MS 1024 512 512 2048 2048 1024 1024 
1024 1024 512 2048 2048 1024 1024 
M6 16384 32768 32768 16384 32768 8192 16384 16384 32768 
16384 32768 32768 16384 32768 8192 16384 8192 32768 
Ml2 32768 32768 65536 16384 32768 16384 65536 32768 32768 
32768 32768 65536 16384 32768 32768 65536 32768 32768 
Ml4 2048 -- 2048 2048 1024 4096 4096 8192 4096 
2048 2048 2048 1024 4096 4096 8192 4096 
M29 2048 2048 2048 2048 
2048 2048 2048 2048 
APS 1024 256 512 256 256 
1024 256 512 512 256 
HGG <8 8 8 8 8 
<8 8 8 8 8 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
;\ 
~ 
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TABLE VI D 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS 
APS, AND HGG 
Patient Patient 
114 115 
AG RHSl!28 29 30 31 32 33 34 35 36 
Ml 16384 8192 8192 16384 16384 16384 8192 8192 8192 
16384 8192 8192 16384 16384 16384 8192 8192 8192 
M3 65536 16384 32768 32768 16384 8192 131072 65536 
65536 32768 32768 32768 32768 8192 131072 65536 
M4 8192 2048 8192 16384 16384 8192 32768 
8192 2048 8192 16384 16384 8192 32768 
MS 512 1024 1024 1024 2048 
1024 2048 1024 2048 2048 
M6 32768 16384 32768 8192 32768 8192 16384 16384 16384 
32768 16384 32768 16384 32768 16384 16384 16384 16384 
Ml2 32768 8192 16384 16384 65536 32768 8192 32768 32768 
32768 8192 32768 16384 65536 32768 8192 32768 32768 
Ml4 4096 1024 1024 2048 2048 4096 4096 
4096 1024 1024 2048 4096 4096 8192 
M29 2048 2048 1024 2048 2048 
2048 2048 1024 2048 2048 
APS 512 2048 1024 2048 4096 
1024 2048 2048 2048 4096 
HGG 16 8 8 16 32 
16 8 8 16 32 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
--
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TABLE VI E 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 116 Patient lt7 
AG RHSl/37 38 39 40 41 42 43 44 45 
Ml 8192 8192 8192 8192 16384 16384 8192 16384 32768 
8192 8192 8192 8192 16384 16384 8192 16384 32768 
M3 65536 65536 32768 32768 32768 65536 32768 131072 32768 
65536 65536 32768 32768 32768 65536 32768 131072 32768 
M4 16384 32768 16384 4096 8192 16384 32768 16384 
16384 32768 16384 4096 8192 16384 32768 16384 
MS 2048 2048 2048 1024 1024 2048 2048 1024 
2048 2048 2048 1024 2048 2048 2048 1024 
M6 16384 16384 16384 16384 16384 16384 16384 65536 32768 
16384 16384 16384 16384 16384 32768 16384 65536 32768 
Ml2 32768 32768 32768 8192 65536 32768 16384 32768 32768 
32768 65536 32768 16384 65536 32768 16384 32768 32768 
Ml4 4096 4096 4096 2048 4096 4096 2048 8192 4096 
4096 8192 8192 2048 4096 4096 2048 8192 4096 
M29 2048 2048 2048 2048 2048 
2048 2048 2048 2048 2048 
APS 2048 2048 4096 2048 4096 
2048 2048 4096 2048 4096 
HGG 16 16 32 8 <8 
16 16 16 8 <8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI F 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS 
APS, AND HGG 
Patient ff 7 Patient 118 
AG RHS//46 47 48 49 50 51 52 53 54 
Ml 8192 8192 16384 16384 8192 8192 512 512 1024 
8192 8192 16384 16384 8192 8192 512 512 1024 
M3 65536 65536 131072 65536 32768 131072 65536 131072 65536 
65536 65536 131072 65536 32768 131072 65536 131072 65536 
M4 16384 16384 16384 16384 16384 2048 16384 16384 16384 
16384 32768 16384 16384 16384 2048 16384. 16384 16384 
MS 2048 2048 2048 2048 2048 128 128 128 128 
2048 2048 2048 2048 2048 128 128 128 128 
M6 8192 32768 32768 32768 32768 16384 32768 32768 32768 
8192 32768 32768 32768 32768 16384 32768 32768 32768 
Ml2 32768 32768 32768 32768 65536 16384 32768 32768 32768 
32768 32768 32768 32768 65536 16384 32768 32768 32768 
Ml4 8192 4096 8192 8192 4096 64 64 64 64 
8192 4096 8192 8192 4096 64 64 64 64 
M29 2048 2048 2048 2048 2048 128 128 128 
2048 2048 2048 2048 2048 128 256 128 
APS 2048 2048 2048 2048 2048 128 64 128 
2048 2048 2048 2048 2048 128 64 128 
HGG 8 8 8 8 8 <8 <8 <8 
8 8 8 8 16 <8 <8 <8 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
1 
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TABLE VI G 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 118 Patient 119 
AG RHSl/55 56 57 58 59 60 61 62 
Ml 32768 512 32768 32768 32768 8192 32768 16384 
32768 512 32768 32768 32768 8192 32768 16384 
M3 131072 16384 131072 131072 131072 65536 131072 
131072 16384 131072 65536 131072 65536 131072 
M4 8192 16384 32768 8192 16384 8192 
8192 16384 32768 8192 16384 16384 
MS 128 256 128 128 1024 1024 
128 256 128 128 2048 1024 
M6 32768 8192 16384 32768 65536 16384 32768 32768 
65536 8192 16384 32768 65536 16384 32768 32768 
Ml2 65536 16384 16384 32768 32768 16384 65536 32768 
65536 16384 16384 32768 32768 16384 65536 32768 
Ml4 512 64 64 64 2048 2048 
512 64 64 64 2048 2048 
M29 256 256 256 128 1024 512 
256 256 256 128 1024 512 
APS 256 64 64 64 4096 2048 
256 64 128 64 4096 4096 
HGG <8 8 <8 8 8 8 
<8 8 <8 <8 8 8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI H 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 119 Patient 1110 
AG RHS/163 64 65 66 67 68 69 70 
Ml 16384 8192 8192 8192 8192 4096 8192 8192 
16384 16384 8192 8192 8192 4096 8192 8192 
M3 131072 32768 32768 16384 65536 131072 131072 32768 
131072 65536 32768 16384 65536 131072 131072 32768 
M4 8192 16384 2048 4096 16384 16384 32768 16384 
8192 16384 2048 8192 16384 16384 32768 16384 
MS 1024 1024 1024 1024 1024 1024 
1024 1024 1024 1024 1024 1024 
M6 16384 8192 16384 32768 16384 32768 32768 32768 
16384 8192 16384 32768 16384 32768 32768 32768 
Ml2 32768 65536 16384 16384 32768 32768 32768 32768 
65536 65536 32768 16384 32768 32768 32768 32768 
Ml4 2048 2048 1024 1024 2048 2048 2048 1024 
2048 2048 1024 1024 2048 2048 2048 1024 
M29 512 512 1024 1024 1024 1024 
512 512 1024 1024 1024 1024 
APS 2048 1024 4096 8192 8192 4096 
2048 2048 8192 8192 8192 4096 
HGG 16 8 32 16 16 32 
16 8 32 16 16 32 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI I 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient Patient 
1110 /Ill 
AG RHS/171 72 73 74 75 76 77 78 
Ml 8192 8192 8192 4096 8192 8192 16384 2048 
8192 8192 8192 4096 8192 8192 16384 2048 
M3 65536 32768 16384 16384 16384 32768 16384 
65536 32768 32768 16384 16384 32768 16384 
M4 16384 2048 2048 4096 16384 16384 
16384 2048 2048 4096 16384 16384 
MS 512 512 1024 1024 
512 512 1024 1024 
M6 32768 16384 16384 32768 8192 8192 32768 8192 
32768 16384 16384 32768 16384 16384 32768 16384 
Ml2 32768 16384 16384 16384 16384 16384 32768 16384 
32768 16384 16384 16384 16384 16384 32768 16384 
Ml4 2048 1024 1024 1024 2048 2048 
2048 1024 1024 1024 2048 2048 
M29 1024 2048 1024 
1024 2048 2048 
APS 4096 4096 2048 
4096 4096 2048 
HGG 16 8 8 
16 8 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI J 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient Patient Patient 
1112 1113 1114 
AG RHS//79 80 81 82 83 84 85 86 
Ml 16384 4096 8192 8192 16384 16384 8192 16384 
16384 4096 8192 16384 16384 16384 16384 16384 
M3 32768 32768 32768 16384 32768 16384 
32768 32768 32768 16384 32768 16384 
M4 4096 32768 8192 4096 
4096 32768 8192 4096 
MS 2048 1024 256 
2048 1024 256 
M6 32768 16384 32768 16384 16384 32768 32768 65536 
32768 16384 32768 16384 16384 32768 32768 65536 
Ml2 32768 8192 16384 16384 65536 32768 65536 16384 
32768 8192 16384 16384 65536 65536 65536 16384 
Ml4 1024 4096 2048 2048 1024 
1024 4096 2048 2048 1024 
M29 2048 
2048 
APS 8192 
8192 
HGG 8 
8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI K 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TOM-PROTEINS, 
APS, AND HGG 
Patient 1115 Patient 1116 Patient 1117 
AG RHS/187 88 89 90 91 92 93 94 95 
Ml 16384 8192 8192 8192 8192 16384 16384 8192 8192 
16384 8192 8192 8192 8192 16384 16384 8192 8192 
M3 32768 32768 131072 32768 32768 32768 32768 
32768 32768 131072 65536 65536 32768 65536 
M4 16384 16384 16384 2048 4096 8192 16384 
16384 16384 16384 2048 4096 8192 16384 
MS 1024 1024 1024 1024 1024 2048 
1024 1024 1024 2048 1024 2048 
M6 32768 2048 8192 16384 32768 32768 16384 16384 16384 
32768 4096 8192 16384 32768 32768 32768 16384 32768 
Ml2 32768 32768 32768 8192 8192 16384 16384 16384 32768 
32768 32768 65536 8192 8192 16384 16384 16384 32768 
Ml4 2048 2048 2048 1024 2048 2048 2048 
2048 2048 2048 1024 2048 2048 2048 
M29 2048 2048 2048 2048 1024 2048 
2048 2048 2048 2048 1024 2048 
APS 2048 4096 4096 2048 4096 2048 
2048 4096 4096 2048 4096 2048 
HGG <8 8 8 <8 8 8 
<8 8 8 <8 8 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI L 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TOM-PROTEINS, 
APS, AND HGG 
Patient 1118 Patient 1119 
AG RHS/196 97 98 99 100 101 102 103 104 
Ml 8192 8192 16384 8192 16384 4096 8192 8192 16384 
8192 8192 16384 8192 16384 4096 8192 8192 32768 
M3 32768 131072 131072 16384 32768 
65536 131072 131072 32768 32768 
M4 16384 8192 4096 4096 8192 
16384 8192 4096 4096 8192 
MS 512 256 256 512 1024 
512 256 256 512 1024 
M6 65536 16384 32768 32768 16384 65536 8192 8192 32768 
65536 16384 32768 32768 16384 65536 16384 16384 32768 
Ml2 8192 16384 32768 32768 16384 16384 16384 16384 32768 
8192 8192 32768 32768 16384 16384 16384 16384 32768 
Ml4 1024 1024 1024 1024 2048 
1024 1024 1024 1024 2048 
M29 256 128 1024 
512 128 1024 
APS 512 512 4096 
512 512 4096 
HGG 32 64 16 
64 64 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI M 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TOM-PROTEINS, 
APS, AND HGG 
Patient 1119 Patient 1120 Patient 1121 
AG RHSt/105 106 107 108 109 llO lll ll2 ll3 
Ml 8192 8192 8192 8192 8192 16384 8192 8192 8192 
8192 8192 8192 8192 8192 16384 8192 8192 8192 
M3 65536 32768 16384 32768 32768 8192 32768 
65536 32768 16384 32768 32768 16384 32768 
M4 8192 8192 2048 16384 16384 2048 16384 
16384 8192 2048 16384 16384 2048 16384 
M5 1024 1024 512 512 512 
1024 1024 512 512 512 
M6 16384 16384 16384 32768 16384 32768 16384 16384 16384 
16384 16384 32768 32768 32768 32768 16384 16384 32768 
Ml2 32768 32768 8192 32768 16384 32768 32768 8192 32768 
32768 32768 8192 32768 16384 32768 32768 8192 32768 
Ml4 2048 2048 1024 1024 1024 1024 2048 
2048 2048 1024 1024 1024 1024 2048 
M29 1024 1024 2048 1024 1024 
1024 2048 2048 1024 1024 
APS 512 1024 4096 2048 2048 
512 1024 4096 2048 2048 
HGG <8 8 8 8 16 
<8 8 16 16 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI N 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 1121 Patient 1122 Patient 1123 
AG RHS//114 115 116 117 118 119 120 121 122 
Ml 16384 8192 8192 16384 8192 8192 16384 32768 16384 
16384 8192 16384 16384 8192 8192 16384 32768 16384 
M3 32768 131072 16384 65536 16384 32768 32768 131072 
32768 131072 16384 65536 16384 32768 32768 131072 
M4 16384 32768 4096 8192 8192 8192 2048 16384 
16384 32768 4096 8192 8192 8192 2048 16384 
MS 1024 1024 1024 1024 1024 1024 1024 
1024 1024 1024 1024 1024 1024 2048 
M6 32768 16384 16384 32768 16384 16384 32768 32768 16384 
32768 16384 16384 32768 16384 16384 32768 32768 16384 
Ml2 32768 32768 16384 16384 16384 16384 65536 32768 32768 
32768 32768 . 32768 16384 16384 16384 65536 32768 32768 
Ml4 2048 2048 2048 2048 2048 2048 1024 4096 
2048 2048 2048 2048 2048 4096 1024 4096 
M29 512 1024 2048 1024 
512 1024 2048 1024 
APS 2048 1024 4096 2048 4096 8192 
2048 1024 4096 4096 8192 8192 
HGG 8 8 8 8 <8 <8 
16 8 16 8 <8 <8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
;';, ,, 
1;' 
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TABLE VI 0 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient If 23 Patient 1124 
AG RHS//123 124 125 126 127 128 129 130 131 
Ml 8192 16384 32768 16384 8192 32768 8192 4096 8192 
8192 16384 32768 16384 16384 32768 8192 4096 8192 
M3 65536 32768 65536 65536 32768 131072 16384 
65536 65536 65536 65536 32768 131072 16384 
M4 16384 16384 16384 16384 16384 16384 1024 2048 
16384 16384 16384 16384 16384 16384 1024 2048 
MS 1024 1024 1024 1024 1024 1024 
1024 1024 1024 1024 1024 1024 
M6 16384 16384 65536 32768 16384 65536 16384 65536 16384 
16384 16384 65536 32768 16384 65536 16384 65536 16384 
Ml2 16384 32768 32768 32768 32768 65536 8192 8192 16384 
16384 32768 65536 32768 32768 65536 8192 8192 32768 
Ml4 4096 4096 4096 4096 4096 4096 1024 
4096 4096 4096 4096 4096 4096 1024 
M29 1024 1024 2048 2048 1024 1024 
1024 1024 2048 2048 1024 1024 
APS 8192 2048 8192 8192 2048 8192 
8192 4096 8192 8192 2048 8192 
HGG <8 <8 16 16 8 8 
<8 8 16 16 8 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI P 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient /124 Patient 1125 
AG RHS/1132 133 134 135 136 137 138 139 140 
Ml 8192 16384 4096 8192 8192 8192 8192 2048 16384 
8192 16384 4096 8192 8192 8192 8192 2048 16384 
M3 65536 32768 131072 131072 65536 131072 262144 65536 
65536 32768 131072 131072 65536 131072 262144 65536 
M4 16384 4096 16384 16384 32768 16384 8192 8192 
16384 4096 16384 16384 32768 16384 8192 8192 
MS 1024 512 1024 1024 1024 1024 1024 1024 
1024 512 1024 1024 1024 1024 1024 1024 
M6 32768 8192 16384 32768 8192 8192 4096 16384 32768 
32768 8192 16384 32768 8192 8192 4096 16384 32768 
Ml2 32768 32768 8192 32768 32768 32768 32768 16384 32768 
65536 32768 8192 32768 32768 32768 32768 16384 32768 
Ml4 2048 1024 2048 2048 2048 2048 2048 2048 
2048 2048 2048 2048 2048 2048 2048 2048 
M29 1024 2048 1024 1024 2048 2048 
1024 2048 1024 1024 2048 2048 
APS 4096 4096 2048 2048 4096 2048 
4096 4096 2048 4096 4096 4096 
HGG 16 32 16 16 8 16 
16 32 16 16 8 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI Q 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 1125 Patient 1126 Patient 1127 
AG RHS//141 142 143 144 145 146 147 148 
Ml 8192 4096 16384 16384 8192 16384 8192 8192 
16384 4096 16384 16384 8192 16384 8192 16384 
M3 32768 32768 32768 65536 16384 
32768 32768 32768 65536 16384 
M4 4096 8192 4096 16384 4096 
4096 8192 4096 16384 4096 
MS 1024 1024 256 1024 512 
1024 1024 256 1024 512 
M6 32768 16384 16384 32768 16384 32768 4096 32768 
32768 16384 16384 32768 16384 32768 4096 32768 
Ml2 32768 8192 32768 32768 16384 32768 16384 32768 
32768 8192 32768 32768 16384 32768 16384 32768 
Ml4 1024 4096 1024 2048 2048 
2048 4096 1024 2048 2048 
M29 2048 
2048 
APS 4096 4096 
4096 4096 
HGG 8 <8 
8 <8 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI R 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TO M-PROTEINS, 
APS, AND HGG 
Patient 1127 Patient 1128 Patient 1129 
AG RHSl/149 150 151 152 153 154 
Ml 8192 8192 8192 4096 16384 16384 
8192 16384 8192 4096 16384 16384 
M3 8192 65536 65536 65536 16384 32768 
16384 65536 65536 65536 16384 32768 
M4 4096 16384 8192 16384 8192 8192 
4096 16384 8192 16384 8192 8192 
MS 2048 1024 512 128 
2048 1024 512 128 
M6 16384 16384 16384 16384 65536 65536 
16384 16384 16384 16384 65536 65536 
Ml2 32768 32768 32768 16384 65536 65536 
32768 32768 32768 16384 65536 65536 
Ml4 2048 4096 2048 2048 64 512 
2048 4096 2048 2048 64 512 
M29 2048 1024 512 
2048 1024 512 
APS 8192 4096 4096 
8192 4096 4096 
HGG 16 8 16 
16 8 16 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VI S 
PASSIVE HA TITERS OF RHEUMATIC HEART SERA TOM-PROTEINS, 
APS, AND HGG 
Patient 1130 
AG RHSt/155 156 157 158 159 160 
Ml 16384 8192 16384 16384 16384 8192 
16384 8192 32768 16384 16384 16384 
M3 16384 32768 131072 32768 65536 65536 
32768 32768 131072 32768 65536 65536 
M4 8192 16384 4096 16384 32768 
8192 16384 4096 16384 32768 
MS 1024 1024 512 1024 1024 
1024 1024 512 1024 1024 
M6 16384 16384 32768 16384 32768 8192 
16384 16384 32768 16384 32768 8192 
Ml2 16384 32768 32768 32768 32768 32768 
16384 32768 32768 32768 32768 32768 
Ml4 2048 2048 4096 2048 4096 8192 
2048 2048 4096 2048 4096 8192 
M29 1024 1024 1024 
1024 2048 1024 
APS 512 4096 2048 1024 
512 4096 2048 1024 
HGG 16 8 8 8 
16 16 8 8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII A 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient Ill 
AG RHS/11 2 3 4 5 6 7 8 9 10 
FPPE 1024 1024 4096 2048 2048 1024 2048 2048 4096 
1024 1024 4096 2048 2048 2048 2048 4096 4096 
FPRE 1024 1024 2048 2048 2048 1024 2048 2048 4096 
1024 1024 2048 2048 2048 1024 2048 2048 4096 
FPSE 64 64 64 256 128 128 64 128 128 128 
6r 128 64 256 128 128 64 128 128 128 
FPHE <8 <8 <8 <8 <3 <8 8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 8 <8 <8 <8 
FPDuE 512 256 512 512 512 512 512 512 
512 256 512 512 512 512 512 512 
FPTE <8 8 8 8 8 8 8 <8 <8 8 
<8 8 8 8 8 8 16 <8 <8 8 
FPBCE 128 256 256 128 128 128 256 
128 256 256 128 128 128 256 
FPCE 64 128 128 128 128 128 182 
64 256 128 128 128 256 128 
FPRaE 2048 1024 1024 2048 
2048 1024 1024 2048 
FPGPE 512 1024 512 2048 
512 1024 512 2048 
FPHoE 1024 1024 1024 1024 
1024 1024 1024 1024 
FPDoE 2048 1024 2048 2048 4096 
2048 1024 2048 2048 4096 
FPGE 64 128 64 64 128 128 
64 128 64 128 128 128 
FPBE 32 32 32 64 32 64 32 32 32 64 
32 32 64 64 32 64 32 32 32 64 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII B 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 112 
AG RHS/111 12 13 14 15 16 17 18 19 20 
FPPE 1024 1024 1024 1024 1024 2048 2048 2048 256 512 
1024 1024 1024 1024 1024 2048 2048 2048 512 512 
FPRE 1024 2048 1024 2048 2048 2048 2048 2048 1024 512 
1024 2048 1024 2048 2048 2048 2048 2048 1024 512 
FPSE 256 256 128 256 128 128 128 256 8 64 
256 256 128 256 128 128 128 256 8 64 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <3 <8 <8 <8 <8 <8 
FPDuE 512 512 512 1024 512 1024 256 
512 512 512 1024 512 1024 256 
FPTE 16 32 8 16 32 8 8 8 <8 8 
16 32 8 16 16 8 <8 8 <8 16 
FPBCE 128 128 256 256 512 32 
256 128 256 256 512 32 
FPCE 128 128 128 256 512 16 
128 128 128 256 512 16 
FPRaE 512 512 512 
512 512 512 
FPGPE 512 512 512 
512 512 512 
FPHoE 1024 2048 1024 
1024 2048 2048 
FPDoE 2048 2048 2048 2048 512 
2048 2048 2048 2048 512 
FPGE 256 128 256 256 128 16 
256 128 256 256 128 16 
FPBE 64 32 64 32 32 64 64 64 16 16 
64 32 64 32 32 64 64 64 16 16 
-- Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII C 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 113 Patient 114 Patient 115 
AG RHSff 21 22 23 24 25 26 27 28 29 30 
FPPE 512 256 512 512 512 256 512 4096 512 
512 256 512 512 512 256 512 4096 512 
FPRE 1024 1024 1024 2048 2048 1024 1024 2048 1024 
1024 1024 1024 2048 2048 1024 1024 2048 1024 
FPSE 16 16 8 32 32 8 32 32 16 32 
8 16 8 32 32 8 32 32 16 32 
FPHE <8 <8 <8 <8 <8 <8 <8 16 16 <8 
<8 <8 <8 <8 <8 <8 <8 16 32 <8 
FPDuE 128 128 256 256 256 256 128 1024 512 
256 128 256 256 256 256 128 1024 512 
FPTE <8 <8 <8 <8 8 <8 8 16 <8 <8 
<8 <8 <8 <8 <8 <8 8 32 <8 <8 
FPBCE 32 16 16 32 64 64 64 128 8 
32 32 32 32 64 64 64 128 8 
FPCE 32 16 16 16 16 16 32 128 16 
32 16 16 32 32 32 32 128 16 
FPRaE 128 128 128 128 128 512 
128 128 128 128 128 512 
FPGPE 64 128 128 64 64 256 
64 128 128 64 64 256 
FPHoE 1024 64 32 32 512 1024 
1024 32 64 32 1024 1024 
FPDoE 1024 2048 1024 2048 2048 1024 512 2048 
1024 2048 2048 2048 2048 1024 512 2048 
FPGE <8 8 <8 8 8 8 64 8 64 
<8 8 <8 8 8 8 64 16 64 
FPBE 8 <8 <8 8 8 32 32 32 32 16 
8 <8 <8 8 8 32 32 32 32 16 
-- Serum sample depleted 
Titers are expressed as reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII D 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient If 5 
AG RHS/f 31 32 33 34 35 36 37 38 39 40 
FPPE 1024 1024 2048 512 2048 1024 1024 2048 4096 256 
1024 2048 2048 512 2048 2048 2048 2048 4096 256 
FPRE 2048 2048 2048 1024 4096 2048 2048 2048 4096 1024 
2048 2048 2048 1024 4096 2048 2048 2048 4096 1024 
FPSE 32 32 16 32 16 32 16 8 16 <8 
32 32 32 32 16 32 16 8 32 8 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 8 <8 <8 <8 <8 <8 
FPDuE 256 512 256 1024 512 512 512 1024 256 
256 512 256 1024 512 512 512 1024 256 
FPTE <8 8 <8 <8 8 <8 8 <8 8 <8 
<8 8 <8 <8 8 <8 8 <8 8 <8 
FPBCE 16 32 32 32 32 32 32 64 64 
16 32 32 32 32 32 32 64 64 
FPCE 16 32 16 16 16 32 16 32 64 
16 32 16 16 32 32 16 64 64 
FPRaE 512 512 1024 512 512 256 2048 
512 512 1024 512 512 512 2048 
FPGPE 256 128 512 128 128 128 512 
256 128 512 128 128 128 512 
FPHoE 1024 64 64 64 64 64 64 512 
1024 64 64 128 64 64 64 512 
FPDoE 1024 2048 2048 2048 2048 2048 2048 2048 1024 
1024 2048 2048 2048 2048 2048 2048 2048 1024 
FPGE 32 32 32 32 32 32 32 32 32 
32 32 32 32 32 32 32 32 32 
FPBE 32 32 64 16 64 32 32 16 128 8 
32 32 64 16 64 32 32 16 128 <8 
Serum sample depleted 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII E 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 117 
AG RHStl41 42 43 44 45 46 47 48 49 50 
FPPE 512 256 512 256 512 256 512 256 256 512 
512 256 512 512 1024 256 512 256 256 512 
FPRE 256 256 512 512 256 256 256 256 256 1024 
256 256 512 512 512 256 512 256 256 1024 
FPSE 8 16 16 8 8 8 16 16 16 16 
8 16 16 16 8 8 16 16 16 16 
FPHE <8 <8 8 <8 <8 <8 <8 <8 8 <8 
<8 <8 8 <8 <8 <8 8 <8 8 <8 
FPDuE 256 128 128 64 64 128 128 128 64 128 
256 128 128 64 64 128 128 128 64 128 
FPTE <8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
FPBCE 128 32 32 32 64 64 64 64 64 
128 64 32 32 128 64 64 64 64 
FPCE 64 64 64 64 64 128 64 32 64 
64 32 64 64 128 128 64 32 64 
FPRaE 128 128 128 128 128 128 128 
128 128 128 128 128 128 128 
FPGPE 128 128 128 128 64 64 128 
128 128 128 128 64 64 128 
FPHoE 512 64 128 128 512 128 128 128 
512 64 128 256 512 128 128 128 
FPDoE 1024 2048 2048 2048 2048 2048 1024 2048 2048 
1024 2048 2048 2048 2048 2048 1024 2048 2048 
FPGE 32 16 32 32 32 16 32 16 32 
32 16 32 32 32 32 32 16 32 
FPBE <8 <8 <8 <8 <8 8 8 8 8 <8 
<8 <8 <8 <8 <8 8 8 8 8 <8 
Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. v 
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TABLE VII F 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 118 Patient 119 
AG RHS/f 51 52 53 54 55 56 57 58 59 60 
FPPE 512 512 512 1024 256 256 256 256 256 
512 512 512 1024 256 512 256 256 256 
FPRE 256 512 512 512 512 512 256 256 256 
512 512 512 512 512 512 256 256 256 
FPSE 16 32 32 32 16 32 16 16 16 32 
16 32 32 32 16 32 16 16 16 32 
FPHE <8 <8 <8 <8 <8 8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
FPDuE 64 64 64 64 128 64 32 64 
64 64 64 64 128 64 32 64 
FPTE <8 <8 <8 <8 <8 8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 8 <8 <8 <8 <8 
FPBCE <8 8 16 <8 16 16 16 8 
<8 8 16 <8 16 16 8 8 
FPCE <8 <8 16 8 16 16 <8 8 
<8 <8 16 <8 16 16 8 8 
FPRaE 256 256 256 128 64 64 128 
256 256 256 256 128 128 128 
FPGPE 128 128 64 64 32 32 64 
128 128 64 64 32 64 64 
FPHoE 256 512 256 64 512 64 64 
256 512 256 128 512 64 64 
FPDoE 2048 1024 2048 1024 1024 2048 1024 
2048 1024 2048 1024 2048 2048 1024 
FPGE 16 16 8 16 8 8 16 8 
16 32 8 16 8 8 16 8 
FPBE 8 16 8 16 8 8 8 8 8 
8 16 8 16 8 8 8 8 8 
Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII G 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 119 Patient t/10 
Ag RHSf/61 62 63 64 65 66 67 68 69 70 
FPPE 2048 2048 2048 2048 1024 512 2048 2048 1024 2048 
2048 2048 2048 2048 1024 512 2048 2048 1024 2048 
FPRE 2048 2048 2048 2048 1024 1024 2048 2048 2048 2048 
2048 2048 2048 2048 1024 1024 2048 2048 2048 2048 
FPSE 64 32 32 32 64 64 128 128 64 64 
32 32 32 32 64 64 128 128 64 64 
FPHE <8 8 <8 8 <8 <8 <8 <8 <8 8 
<8 8 <8 8 <8 <8 <8 <8 <8 8 
FPDuE 512 512 1024 512 128 128 512 512 256 256 
512 512 1024 512 128 128 512 512 256 256 
FPTE <8 <8 <8 <8 <8 <8 <8 <8 8 8 
<8 <8 <8 <8 <8 <8 <8 <8 8 8 
FPBCE 64 64 64 64 128 64 128 128 256 128 
64 64 64 64 128 128 128 256 256 128 
FPRaE 1024 1024 1024 1024 512 512 512 1024 
1024 1024 1024 1024 1024 512 512 1024 
FPGPE 128 128 128 256 64 64 64 64 
128 128 128 512 128 128 128 64 
FPHoE 128 512 512 512 1024 512 1024 128 
128 512 512 512 1024 512 1024 128 
FPDoE 2048 2048 2048 2048 1024 2048 2048 2048 2048 
2048 2048 2048 2048 1024 2048 2048 2048 2048 
FPGE 32 32 32 32 64 64 128 32 32 64 
32 32 32 32 64 64 128 32 32 64 
FPBE 64 64 64 32 8 8 32 16 16 32 
64 64 64 32 16 8 32 16 16 32 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII H 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 1110 Patient 1/11 Patient 1112 
AG RHS/171 72 73 74 75 76 77 78 79 80 
FPPE 1024 512 1024 512 1024 2048 2048 512 
1024 512 1024 512 1024 2048 2048 512 
FPRE 1024 1024 1024 1024 1024 2048 4096 1024 
1024 1024 1024 1024 1024 2048 4096 1024 
FPSE 64 16 32 32 32 32 32 32 64 32 
64 32 32 32 32 32 32 32 64 32 
FPHE <8 <8 <8 <8 <8 <8 8 <8 <8 <8 
<8 <8 <8 <8 <8 <8 8 <8 8 <8 
FPDuE 256 1024 512 512 1024 512 
256 1024 512 512 1024 512 
FPTE <8 <8 <8 <8 <8 8 8 8 <8 <8 
<8 <8 <8 <8 <8 8 8 8 <8 <8 
FPBCE 64 32 32 64 128 64 
64 32 32 64 128 128 
FPCE 128 64 32 64 64 128 
128 64 32 64 64 128 
FPRaE 512 512 512 
512 512 1024 
FPGPE 64 128 128 
64 256 128 
FPHoE 512 512 2048 
512 512 2048 
FPDoE 2048 1024 1024 2048 2048 
2048 1024 1024 2048 2048 
FPGE 32 32 16 32 32 64 
32 32 16 32 32 64 
FPBE 16 32 32 32 32 32 32 32 
32 32 32 32 32 64 32 32 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII I 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 1112 Patient /113 Pat. 1114 Patient 1115 
AG RHS/181 82 83 84 85 86 87 88 89 90 
FPPE 1024 1024 512 256 1024 4096 2048 2048 
1024 1024 512 256 1024 4096 2048 2048 
FPRE 1024 2048 512 512 1024 2048 1024 2048 
1024 2048 512 1024 1024 2048 1024 2048 
FPSE 64 64 32 16 32 32 64 64 64 128 
128 128 32 16 32 32 64 64 64 128 
FPHE <8 <8 16 <8 <8 <8 <8 <8 <8 <8 
<8 <8 16 <8 <8 <8 <8 <8 <8 <8 
FPDuE 512 256 128 128 1024 512 512 512 
512 256 128 128 1024 512 512 512 
FPTE <8 <8 8 <8 <8 8 8 8 8 <8 
<8 <8 8 <8 <8 8 8 8 8 <8 
FPBCE 256 64 32 512 64 128 128 256 
256 64 32 512 32 64 64 256 
FPCE 256 128 64 1024 32 32 32 
256 128 64 1024 32 64 32 
FPRaE 256 1024 1024 1024 
256 1024 1024 1024 
FPGPE 128 32 1024 512 1024 
128 32 1024 512 1024 
FPHoE 1024 256 1024 1024 512 512 
1024 256 1024 1024 512 512 
FPDoE 1024 2048 2048 1024 2048 2048 2048 
1024 2048 2048 1024 2048 2048 2048 
FPGE 64 128 32 64 32 32 32 
128 128 32 64 64 32 32 
FPBE 32 32 32 32 32 32 32 32 
32 64 32 32 32 32 32 64 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII J 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 1116 Patient lfl7 Patient lfl8 Patient 1119 
AG RHS/191 92 93 94 95 96 97 98 99 100 
FPPE 1024 2048 1024 1024 2048 1024 256 
1024 2048 2048 2048 2048 2048 256 
FPRE 1024 2048 1024 1024 00 00 2048 2048 512 
1024 2048 1024 1024 2048 2048 512 
FPSE 128 128 64 32 32 32 64 32 16 64 
128 128 64 32 32 64 64 64 16 64 
FPHE <8 <8 <8 <8 <8 <8 16 <8 <8 <8 
<8 <8 <8 <8 <8 <8 16 <8 <8 <8 
FPDuE 512 256 512 256 128 256 512 512 
512 256 512 256 128 256 512 512 
FPTE 8 8 32 32 64 <8 8 <8 16 <8 
8 8 32 32 64 <8 8 <8 16 <8 
FPBCE 32 64 64 128 128 32 
32 128 64 128 128 32 
FPCE 32 64 128 64 128 128 32 
32 64 128 64 128 128 32 
FPRaE 512 256 256 1024 512 
512 512 256 1024 512 
FPGPE 512 256 256 256 256 
512 256 256 256 256 
FPHoE 1024 128 128 2048 128 
1024 128 128 2048 128 
FPDoE 1024 2048 2048 2048 4096 2048 1024 
1024 2048 2048 2048 4096 2048 1024 
FPGE 64 32 32 16 32 <8 32 
64 32 32 32 32 <8 32 
FPBE 32 32 16 8 32 8 8 
32 32 16 8 32 8 8 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII K 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient 1119 Patient #20 
AG RHS/1101 102 103 104 105 106 107 108 109 110 
FPPE 512 2048 512 2048 1024 512 2048 
512 2048 512 2048 1024 512 2048 
FPRE 512 2048 512 1024 1024 1024 2048 
512 2048 512 1024 1024 1024 2048 
FPSE 32 64 64 64 64 32 32 16 64 32 
64 64 64 64 64 32 32 16 64 32 
FPHE <8 <8 <8 <8 <8 8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 16 <8 <8 <8 <8 
FPDuE 512 512 512 512 256 512 
512 512 512 512 256 512 
FPTE <8 <8 <8 <8 <8 8 8 16 16 8 
<8 <8 <8 <8 <8 8 8 16 16 8 
FPBCE 32 128 32 64 32 64 
32 128 64 64 32 64 
FPCE 32 64 32 64 32 64 
32 64 32 64 64 64 
FPRaE 1024 256 512 1024 
1024 256 512 1024 
FPGPE 512 128 256 256 
512 128 256 256 
FPHoE 2048 64 128 256 
2048 64 128 256 
FPDoE 1024 2048 2048 2048 2048 
1024 2048 2048 2048 2048 
FPGE 32 128 32 64 32 64 
32 128 32 64 32 64 
FPBE 8 8 32 8 32 32 32 32 32 
8 8 32 8 32 32 32 32 64 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of ·the serum dilution. 
All results are in duplicate. 
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TABLE VII L 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Pat. //20 Patient 1/21 Patient 1122 Patient 1123 
AG RHSl!lll 112 113 114 115 116 117 118 119 120 
FPPE 2048 512 2048 2048 512 512 1024 2048 1024 
2048 512 2048 2048 512 512 1024 2048 1024 
FPRE 1024 1024 2048 2048 1024 1024 2048 2048 2048 1024 
1024 1024 2048 2048 1024 1024 2048 2048 2048 2048 
FPSE 16 64 64 64 32 64 128 32 64 64 
16 64 64 64 32 64 128 32 64 128 
FPHE <8 <8 <8 <8 <8 <8 <8 <8 8 <8 
<8 <8 <8 <8 <8 <8 <8 <8 8 <8 
FPDuE 512 512 512 1024 256 512 1024 512 256 
512 512 512 1024 256 512 1024 512 256 
FPTE <8 <8 16 <8 <8 <8 <8 <8 16 8 
<8 <8 16 <8 <8 <8 <8 <8 16 8 
FPBCE 64 64 64 128 32 64 64 128 128 
64 128 64 128 64 64 64 64 128 
FPCE 64 128 64 128 64 64 64 64 128 
64 128 64 128 64 64 64 64 128 
FPRaE 512 512 1024 256 512 512 1024 
512 512 1024 256 512 1024 1024 
FPGPE 256 512 1024 256 256 512 256 
256 512 1024 256 256 512 256 
FPHoE 128 1024 2048 512 256 2048 1024 
128 1024 2048 512 256 2048 1024 
FPDoE 2048 2048 2048 2048 1024 2048 2048 2048 
2048 2048 2048 2048 2048 2048 2048 2048 
FPGE 32 64 64 64 32 128 128 64 128 
32 64 64 64 32 128 128 64 128 
FPBE 32 32 32 64 32 32 32 32 32 
32 32 32 32 32 32 32 32 32 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII M 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient tl23 Patient t/24 
AG RHStll21 122 123 124 125 126 127 128 129 130 
FPPE 512 2048 2048 4096 4096 4096 2048 4096 
512 2048 2048 4096 4096 4096 2048 4096 
FPRE · 1024 4096 4096 4096 4096 4096 4096 4096 
1024 4096 4096 4096 4096 4096 4096 4096 
FPSE 64 64 256 128 256 256 256 256 128 64 
64 64 256 128 256 256 256 256 128 64 
FPHE <8 <8 8 <8 8 16 32 <8 8 8 
<8 <8 8 <8 8 16 64 <8 8 8 
FPDuE 256 512 512 1024 1024 1024 1024 512 
256 512 512 1024 1024 1024 1024 512 
FPTE 8 8 8 8 16 16 16 16 8 <8 
8 8 8 8 16 16 16 16 8 <8 
FPBCE 64 64 128 128 512 512 512 512 
64 128 128 256 512 512 512 512 
FPCE 128 128 64 128 256 256 256 256 
128 128 128 128 256 256 256 256 
FPRaE 2048 2048 1024 1024 1024 1024 1024 
2048 2048 1024 1024 1024 1024 1024 
FPGPE 512 1024 1024 1024 1024 1024 1024 
1024 1024 1024 1024 1024 1024 1024 
FPHoE 1024 512 512 1024 1024 1024 1024 
1024 512 1024 1024 1024 1024 1024 
FPDoE 2048 2048 2048 2048 2048 2048 2048 
2048 2048 2048 2048 2048 2048 2048 
FPGE 128 128 256 256 256 128 256 
128 128 256 256 256 128 256 
FPBE 32 128 128 128 128 128 128 128 
32 128 128 128 128 128 128 128 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII N 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Patient /124 Pat. 1125 
AG RHSl/131 132 133 134 135 136 137 138 139 140 
FPPE 1024 4096 2048 4096 4096 4096 4096 4096 512 
1024 4096 2048 4096 4096 4096 4096 4096 512 
FPRE 1024 4096 2048 4096 2048 4096 2048 2048 1024 
1024 4096 2048 4096 2048 4096 2048 2048 1024 
FPSE 64 128 256 128 128 256 256 128 128 128 
64 128 256 128 128 256 256 128 128 128 
FPHE <8 <8 8 8 <8 <8 <8 <8 <8 <8 
<8 <8 8 8 <8 <8 <8 <8 <8 <8 
FPDuE 256 1024 1024 1024 1024 1024 1024 1024 512 
256 1024 1024 1024 1024 1024 1024 1024 512 
FPTE <8 16 8 8 8 16 16 8 8 <8 
<8 16 8 8 8 16 16 8 8 <8 
FPBCE 16 256 64 256 256 128 256 128 64 
32 256 128 256 256 128 256 128 64 
FPCE 32 256 128 256 256 128 512 256 32 
32 256 128 256 256 128 512 256 64 
FPRaE 2048 2048 2048 2048 1024 1024 
2048 2048 2048 2048 1024 1024 
FPGPE 1024 2048 1024 1024 1024 1024 
1024 2048 2048 1024 1024 1024 
FPHoE 1024 2048 1024 1024 1024 1024 1024 
1024 2048 1024 2048 1024 1024 2048 
FPDoE 2048 2048 2048 2048 2048 2048 2048 2048 2048 
2048 2048 2048 2048 2048 2048 2048 2048 2048 
FPGE 128 128 128 128 128 128 128 8 
128 128 128 128 128 128 128 8 
FPBE 32 64 64 64 64 64 64 64 128 32 
32 128 64 64 64 64 64 64 128 32 
Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII 0 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTES 
Pat. lt25 Patient 1126 Patient 1127 
AG RHS/1141 142 143 144 145 146 147 148 149 150 
FPPE 2048 512 512 1024 1024 2048 512 2048 
2048 512 512 2048 1024 2048 512 2048 
FPRE 2048 512 512 1024 2048 2048 1024 2048 
2048 512 512 1024 2048 2048 1024 2048 
FPSE 256 128 16 8 64 64 64 64 8 64 
256 128 16 8 64 64 64 64 8 64 
FPHE <8 8 <8 <8 <8 <8 <8 <8 <8 64 
<8 8 <8 <8 <8 <8 <8 <8 <8 64 
FPDuE 1024 1024 512 256 512 512 512 
1024 1024 512 256 512 512 512 
FPTE 8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
8 <8 <8 <8 <8 <8 <8 <8 <8 <8 
FPBCE 128 32 16 32 32 64 64 
256 32 32 32 32 64 64 
FPCE 256 64 16 32 32 64 64 
256 64 16 32 32 64 64 
FPRaE 128 1024 1024 
128 1024 1024 
FPGPE 128 256 512 
128 256 512 
FPHoE 1024 64 128 512 
1024 64 128 512 
FPDoE 2048 2048 2048 4096 1024 2048 
2048 2048 2048 4096 1024 2048 
FPGE 128 8 64 32 64 <8 64 
128 8 64 32 64 <8 64 
FPBE 128 8 8 32 64 64 32 8 64 
128 8 8 32 64 64 32 8 64 
-- Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
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TABLE VII P 
HA TITERS OF RHEUMATIC HEART SERA TO STABILIZED ERYTHROCYTE 
Patient 1128 Patient #29 Patient #30 
AG RHSltl51 152 153 154 155 156 157 158 159 160 
FPPE 2048 2048 512 512 1024 256 512 512 512 256 
2048 2048 512 512 1024 256 512 512 512 512 
FPRE 2048 1024 512 512 1024 512 512 1024 512 2048 
2048 1024 512 512 1024 512 512 1024 512 2048 
FPSE 16 32 16 16 32 64 32 64 64 32 
32 32 16 16 32 64 32 64 64 32 
FPHE <8 <8 <8 <8 <8 8 <8 <8 <8 <8 
<8 <8 <8 <8 <8 8 <8 <8 <8 8 
FPDuE 1024 512 64 128 512 256 256 256 256 256 
1024 512 64 128 512 256 256 256 256 256 
FPTE 16 16 <8 <8 <8 8 <8 <8 <8 <8 
16 16 <8 <8 <8 8 <8 <3 <8 <8 
FPBCE 128 64 16 8 256 128 64 128 64 
128 64 16 8 256 256 64 128 128 
FPCE 64 64 16 8 256 128 128 128 64 
64 64 16 8 256 128 128 128 64 
FPRaE 1024 1024 128 128 128 128 
1024 1024 128 128 256 128 
FPGPE 512 256 128 256 128 128 
512 256 128 256 128 128 
FPHoE 512 512 1024 1024 1024 2048 2048 
512 512 1024 1024 1024 2048 2048 
FPDoE 2048 2048 1024 2048 2048 2048 1024 2048 2048 
2048 2048 1024 2048 2048 2048 1024 2048 2048 
FPGE 32 32 32 32 64 32 32 32 16 
32 32 32 32 64 32 32 32 16 
FPBE 64 64 16 8 64 16 16 16 16 16 
64 64 16 8 64 16 16 16 16 16 
Serum sample depleted. 
Titers are expressed as the reciprocal of the serum dilution. 
All results are in duplicate. 
TABLE VIII 
DUNCAN'S MULTIPLE RANGE TEST FOR NORMAL HUMAN SERA vs M-PROTEINS 
Ordered geometric mean titers - expressed as Log10 
MS 
2.742 
M29 Ml4 Ml 
2.922 2.9SO 3.S82 
M6 
3.902 
TABLE IX 
M4 
4.0S3 
Ml2 
4.237 
M3 
4.744 
DUNCAN'S MULTIPLE RANGE TEST FOR PHARYNGITIS SERA vs M-PROTEINS 
Ordered geometric mean titers - expressed as Log10 
MS 
2.177 
Ml4 
2.48S 
M29 
2.847 
Ml 
3.SS6 
M4 Ml2 
3.780 4.244 
TABLE X 
M6 
4.262 
M3 
4.60S 
8S 
DUNCAN'S MULTIPLE RANGE TEST FOR RHEUMATIC HEART SERA vs M-PROTEINS 
Ordered geometric mean titers - expressed as Log10 
MS 
2.902 
M29 Ml4 
3.07S 3.274 
M4 
3.936 
Ml 
4.021 
M6 
4.3Sl 
Ml2 
4.416 
M3 
4.627 
Any two means not underscored by the same line are significantly different. 
TABLE XI 
DUNCAN'S MULTIPLE RANGE TEST FOR NORMAL HUMAN SERA vs STABILIZED ERYTHROCYTES 
Ordered geometric mean titers - expressed as Log10 
FPHE FPTE FPBE FPGE FPSE FPCE FPBCE FPHoE FPGPE FPDuE FPRaE FPPE FPDoE FPRE 
0.648 0.665 1.033 1.233 1.529 1.608 1.661 2.255 2.311 2.438 2.512 2.805 3.038 3.172 
TABLE XII 
DUNCAN'S MULTIPLE RANGE TEST FOR PHARYNGITIS SERA vs STABILIZED ERYTHROCYTES 
Ordered geometric mean titers - expressed as Log10 
FPTE FPHE FPBE FPSE FPBCE FPGE FPCE FPGPE FPDuE FPRaE FPHoE Ff PE FPRE FPDoE 
0.692 0.740 1.414 1.776 1.780 1.793 1.883 2.305 2.546 2.774 2.859 2.954 3.118 3.311 
Any two means not underscored by the same line are significantly different. 
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TABLE XIII 
DUNCAN'S MULTIPLE RANGE TEST FOR RHEUMATIC HEART SERA vs STABILIZED ERYTHROCYTES 
Ordered geometric mean titers - expressed as Log10 
FPHE FPTE FPBE FPGE FPSE FPCE FPBCE FPGPE FPDuE FPHoE FPRaE FPPE FPRE FPDoE 
0.676 0.815 1.445 1.597 1.741 1.848 1.887 2.406 2.625 2.671 2.718 3.051 3.102 3.249 
Any two means not underscored by the same line are significantly different. 
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TABLE XIV 
COMPARISON OF SERA TO A SELECTED HIGH TITER FOR EACH ANTIGEN 
Selected Normal Human Pharyngitis 
Antigen Titer Sera Sera R.H. Sera 
Ml >16384 *6% 20% 87% 
M3 >131072 18% 0% 50% 
M4 >16384 58% 10% 70% 
MS >2048 8% 0% 28% 
M6 >32768 4% 50% 90% 
Ml2 >32768 18% 20% 90% 
M14 >4096 2% 0% 37% 
M29 >2048 10% 20% 67% 
APS >2048 2% 50% 80% 
HGG >8 8% 70% 100% 
FPPE >2048 14% 0% 70% 
FPRE >4096 14% 0% 20% 
FPSE >64 20% 80% 63% 
FPHE o- >8 10% 40% 50% 
FPDuE >1024 6% 20% 47% 
FPTE >8 18% 20% 83% 
FPBCE >128 8% 0% 60% 
FPCE >128 10% 30% 57% 
FPRaE >1024 10% 40% 56% 
FPGPE >512 18% 10% 52% 
FPHoE >1024 12% 80% 70% 
FPDoE >2048 16% 100% 93% 
FPGE >32 36% 100% 90% 
FPBE >32 22% 60% 90% 
*6% of the normal human sera tested possess titers >16384 to Ml 
protein. 
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TABLE XV 
STATISTICAL INFORMATION ON NORMAL HUMAN SERA 
Geometric Standard Standard 
Mean Variance Deviation Error of Minimum Maximum 
Antigen Titer Log10 LoglO Mean LoglO Titer Titer 
Ml 3822 0.2044 0.4521 0.0639 256 32768 
M3 55491 0.0834 0.2889 0.0408 8192 131072 
M4 11309 0.1932 0.4395 0.0621 24 32768 
MS 552 0.2048 0.4526 0.0640 8 4096 
M6 7985 0.0906 0.3010 0.0425 1024 32768 
Ml2 17294 0.0269 0.1641 0.0232 8192 32768 
Ml4 892 0.3102 0.5570 0.0787 <8 4096 
M29 837 0.0428 0.2070 0.0292 256 3061 
APS 329 0.1178 0.3432 0.0490 32 2048 
HGG <8 0.0208 0.1442 0.0206 <8 32 
FPPE 640 0.1268 0.5360 0.0503 128 4096 
FPRE 1496 0.0899 0.2999 0.0424 256 4096 
FPSE 34 0.0765 0.2766 0.0391 16 256 
FPHE o- <8 0.0187 0.1368 0.0193 <8 24 
FPDuE 274 0.0785 0.2803 0.0396 128 1024 
FPTE <8 0.0208 0.1442 0.0204 <8 16 
FPBCE 46 0.0630 0.2511 0.0355 16 256 
FPCE 41 0.0859 0.2931 0.0414 <8 128 
FPRaE 325 0.1110 0.3331 0.0471 64 1024 
FPGPE 205 0.0919 0.3031 0.0428 63 1024 
FPHoE 180 0.2313 0.4809 0.0680 32 2048 
FPDoE 1094 0.0229 0.1515 0.0214 512 2048 
FPGE 17 o. 2118 0.4602 0.0650 <8 128 
FPBE 11 0.1520 0.3898 0.0551 <8 96 
M-Proteins 4390 
Erythro. 84 
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TABLE XVI 
STATISTICAL INFORMATION ON PHARYNGITIS SERA 
Geometric Standard Standard 
Mean Variance Deviation Error of Minimum Maximum 
Antigen Titer LoglO LoglO Mean Log10 Titer Titer 
Ml 3606 0.4246 0.6516 0.2060 512 32768 
M3 40342 0.0412 0.2032 0.0642 16384 65536 
M4 6030 0.0542 0.2328 0.0736 4096 16384 
MS 150 0.5849 0.7648 -.2418 8 1024 
M6 18293 0.1318 0.3631 0.1148 4096 32768 
Ml2 17560 0.0291 0.1708 0.0540 8192 32768 
Ml4 306 0. 7248 0.8513 0.2692 8 2048 
M29 703 0.1433 0.3786 0.1197 256 4096 
APS 3141 0.1420 0.3762 0.1254 1531 8192 
HGG 10 0.3515 0.5938 0.1979 <8 32 
FPPE 901 0.0218 0.1479 0.0467 512 1531 
FPRE 1312 0.0408 0.2020 0.0639 512 2048 
FPSE 60 0.0694 0.2635 0.0833 16 128 
FPHE.0- <8 0.0344 0.1856 0.0586 <8 12 
FPDuE 352 0.0829 0.2880 0.0910 128 1024 
FPTE <8 0.0412 0.2031 0.0642 <8 16 
FPBCE 60 0.0028 0.0532 0.0168 48 64 
FPCE 77 0.0369 0.1922 0.0607 32 128 
FPRaE 595 0.0608 0.2467 0.0780 256 1024 
FPGPE 202 0.0604 0.2459 0.0777 64 512 
FPHoE 724 0.1460 0.3821 0.1208 64 1024 
FPDoE 2048 0.0000 0.0000 0.0000 2048 2048 
FPGE 62 0.0736 0.2714 0.0858 32 128 
FPBE 26 0.1016 0.3188 0.1008 8 128 
M-Proteins 3130 
Erythro. 138 
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TABLE XVII 
STATISTICAL INFORMATION ON RHEUMATIC HEART SERA 
Geometric Standard Standard 
Mean Variance Deviation Error of Minimum Maximum 
Antigen Titer Log10 LoglO Mean Log10 Titer Titer 
Ml 10350 0.0899 0.2999 0.0555 512 32768 
M3 46800 0.0835 0.2889 0.0535 8195 262144 
M4 9689 0.1072 0.3274 0.0606 1024 32768 
MS 815 0.0752 0.2742 0.0508 128 2048 
M6 21800 0.0586 0.2420 0.0448 3072 65536 
Ml2 26995 0.0618 0.2485 0.0460 8192 65536 
Ml4 1707 0.1700 0.4123 0.0764 64 8192 
M29 1087 0.0557 0.2361 0.0437 128 2048 
APS 2254 0.5907 0.7683 0.1604 64 8192 
HGG 11 0.1570 0.3958 0.0808 <8 64 
FPPE 1056 0.1157 0.3401 0.0630 256 4096 
FPRE 1275 0.0857 0.2939 010542 256 4096 
FPSE 48 0.0632 0.4040 0.0748 <8 256 
FPHE o- <8 0.0399 0.1997 0.0370 <8 64 
FPDuE 354 0.1056 0.3249 0.0601 32 1024 
FPTE <8 0.0655 0.2560 0.0474 <8 64 
FPBCE 73 0.1549 0.3936 0.0287 <8 512 
FPCE 65 0.1495 0.3867 0.0277 <8 512 
FPRaE 485 0.0869 0.2948 0.0161 96 2048 
FPGPE 248 0.1092 0.3304 0.0202 32 2048 
FPHoE 399 0.1519 0.3898 0.0281 48 2048 
FPDoE 2126 010159 0.1284 0.0029 512 4096 
FPGE 40 0.1415 0.3761 0.0262 <8 256 
FPBE 26 0 .1471 0.3836 0.0272 <8 128 
M-Proteins 6700 
Erythro. 133 
TABLE XVIII 
"T-TEST" VALUES TO DEMONSTRATE SIGNIFICANT DIFFERENCES BETWEEN MEANS 
OF NORMAL, PHARYNGITIS, AND RHEUMATIC HEART SERA TO ALL ANTIGENS 
T values Sig. Diff. T values Sig. Diff. T values Sig. Diff. 
for means denoted at for means denoted at for means denoted at 
Antigen NHS vs PS 1% level NHS vs RHS 1% level RHS vs PS 1% level 
Ml 0.293 0 11.315 R 6.865 R 
M3 5.060 N 3.743 N 2.300 0 
M4 4.483 N 1. 762 0 5.702 R 
MS 5.878 N 4.571 R 9.424 R 
M6 10.309 p 32.439 R 2.583 0 
Ml2 0.686 0 20.737 R 9.041 R 
Ml4 3.418 N 4.596 R 6.280 R 
M29 3.548 N 10.059 R 5.952 R 
APS 22.455 p 12.405 R 0.813 0 
HGG 12.878 p 32.386 R 0.331 0 
FPPE 3.803 p 7.476 R 1.924 0 
FPRE 1.943 0 3.297 N 0.432 0 
FPSE 9.123 p 6.050 R 1.681 0 
FPHE 11. 965 p 4.552 R 4.243 p 
FPDuE 3.795 p 5.268 R 0.073 0 
FPTE 3.072 p 14 .419 R 0.593 0 
FPBCE 6.311 p 8.846 R 1.881 0 
FPCE 9.874 p 7.757 R 1.572 0 
FPRaE 7.114 p 7.174 R 2.862 p 
FPGPE 0.196 0 3.609 R 2.419 0 
FPHoE 7. 771 p 7.261 R 4.463 p 
FPDoE 39.931 p 41.448 R 15.953 R 
FPGE 8.276 p 8.419 R 3. 971 p 
FPBE 7.400 p 10.735 R 0.017 R 
M-Proteins 5.805 N 13. 856 R 15.209 R 
Erythro. 11. 915 p 23.010 R 1.746 0 
., ..... ,,au ** M tk · * * ·eeeeetnnri~ -
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TABLE XVIII (continued) 
N Normal significantly higher titer. 
P Pharyngitis significantly higher titer. 
R = Rheumatic heart significantly higher titer. 
0 = No significant difference between titers. 
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IV. DISCUSSION 
The predominant objective of this investigation had been to 
determine the antibody levels in sera of healthy and convalescent 
streptococcal infected adults to a series of streptococcal antigens 
in order that an antibody profile for human serum could be initiated. 
Further an attempt was made to correlate these antibody profiles to 
heterologous erythrocyte agglutinin titers obtained for the same sera. 
Prior to collecting data for this purpose it was necessary to 
adsorb the streptococcal antigens onto the surface of stabilized 
erythrocytes to provide an antigen coated erythrocyte capable of 
detecting small amounts of anti-streptococcal antibodies. The finding 
that not all M-proteins in this study coated erythrocytes under identi-
cal conditions may have some bearing on the proteins' physical 
and chemical differences. With the exception of type 1 M protein 
the optimum coating condition for the M-proteins obtained from Abbott 
Laboratories and extracted by the method of Fox (7) were identical. 
The erythrocyte coating conditions for M4 and M29 obtained from Dr. 
Lange at Loyola and prepared by the method of Lange (19) and Lancefield 
(16) differed from M proteins obtained at Abbott and differed from 
each other. It was thought that the different methods used to extract 
M protein could be reason for the varying coating conditions observed 
for the different M-proteins. The extraction method of Fox (7) 
utilized an alkaline buffer system whereas the Lancefield (16) method 
was by the hot acid extraction procedure. If the difference in coating 
conditions were due primarily to the methods by which the M proteins 
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were extracted then the M4 and M29 preparations, both of which were 
extracted under identical conditions, should have had their coating 
conditions more closely related. It is more probable that these 
coating differences can be attributed to the amino acid composition of 
each specific type of M-protein (26). The M-types employed here 
include those which show the greatest incidence within the Metropolitan 
Chicago area. 
After the sera were tested with the various antigens it was 
found that all sera from patients with streptococcal pharyngitis or 
rheumatic heart possessed hemagglutinating antibody that reacts with 
all the M-proteins tested in this survey. Some M proteins apparently 
possess common antigenic determinants which could account for extensive 
cross reactivity between M types as suggested by Lancefield (17), 
demonstrated for Ml2 and M3 by Fox (8) and between Ml2, M31, and M39 
as shown by Zimmerman (28). Extensive cross reactivity between M 
proteins could therefore account for antibody to each M type being 
present in all sera of convalescent streptococcal infected patients. 
Normal adult humans also contain anti-M protein antibody in their 
serum with the exception that 4% (#11 and #46) possessed no detectable 
antibody to type Ml4 protein. Healthy adult individuals probably 
contain antibody to many different M-proteins not only by possible 
past infection with each various streptococcal strain but more likely 
by possessing antibody to M proteins which cross react with other 
M types. The two normal sera (#11 and #46) which lack detectable 
antibody to Ml4 provide further information on the cross reactivity 
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problem of the M proteins. First, if Ml4 shares determinants with 
the other M proteins used in this study, these two normal sera obviously 
did not form antibody to such a determinant. Secondly, the antibodies 
responsible for agglutinating erythrocytes coated with other than 
Ml4 protein do not cross react with Ml4. Furthermore these two normal 
sera possessed substantially lower titers to Ml (Sl2 and 2S6) and MS 
(8 and 32) compared to the geometric mean titer of all normal sera 
for these proteins (3822 for Ml and SS2 for MS) even though their 
remaining M-protein titers are comparable to the geometric mean titer 
for these proteins. This is evidence that antibody formed to Ml4 
may enhance titers to Ml and MS. Lack of detectable anti-Ml4 antibody 
in these two normal sera could simply reflect innnunological innocence 
by these individuals to this protein. And since these sera also showed 
depressed anti Ml and MS titers it is possible that these normal indiv-
iduals also were not exposed to Ml or MS protein either. The reactivity 
found in these two sera to Ml and MS could then be attributed to a 
cross reacting antibody formed to another M protein. 
There is further evidence that antibody to Ml4 protein may 
enhance passive hemagglutination titers to Ml and MS. Normal serum #31 
possessed lower than average titers to Ml4 (1:128), MS (1:96), and Ml 
(1:1024). In addition, normal serum #3S which possessed the highest 
. 
titer of normal sera to Ml4 (1:4096) also had the highest MS (1:4096) 
and Ml (1:16384) titer of the normal sera tested. This correlation 
can partially be substantiated in sera from pharyngitis patients. 
Patients #6, 7, and 8 collectively had the lowest Ml4, MS, and Ml 
r 
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titers of this group. However, in contrast to the finding in normal 
sera, pharyngitis patients #1 and #2 who possessed the highest Ml4 
and MS titer in the pharyngitis group did not possess the highest Ml 
titer of their group, although their anti Ml titer is above the geometric 
mean Ml titer. The rheumatic heart group is similar to the pharyngitis 
group in this respect. Patient #8 which possessed the lowest Ml4 titer 
also had the lowest MS and Ml titer for the group. Patient #6 
possessed the highest Ml4 and MS titer but as in the pharyngitis group, 
not the highest titer to Ml. To verify whether antibody formed to 
Ml4 does indeed enhance titers to Ml and MS absorbtion and inhibition 
experiments involving these proteins would need be performed. 
Employing the Duncan's multiple range test which depicts signi-
ficant differences between means Table VIII shows that with the excep-
tion of Ml4 and M29, all the M proteins tested manifest significantly 
different mean hemagglutinating titers in the normal serum group. 
Contrary to this, the pharyngitis serum group did not possess any mean 
M-protein titer which was significantly different from all the other 
mean protein titers. Each mean M-protein titer could not be distinguished 
from at least one other mean M-protein titer in this group. This 
observation that not one M protein could demonstrate a significantly 
different mean hemaggluting titer from each of the other M proteins 
is consistent with the cross reactive properties and relatedness of 
the M proteins. The pharyngitis group could be expected to show a 
lesser degree of distinction in its titers to M proteins than would 
be expected for the normal serum group since this pharyngitis serum 
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is from convalescent patients with confirmed streptococcal infections. 
A recent streptococcal infection with an organism capable of inducing 
antibody to more than one specific type of streptococcus could manifest 
such a lesser degree of distinction to M types in patients contracting 
this infection. 
When the rheumatic heart serum group was analysed by means of 
the Duncan's multiple range test it could be seen that this group did 
not distinguish between the mean titer of Ml and M4, nor between 
M6 and Ml2, however the remaining mean M protein titers were signifi-
cantly different from all mean M protein titers. Whether this obser-
vation and those seen in the normal and pharyngitis groups are peculiar 
for these particular populations alone or whether this phenomenon is 
characteristic of all rheumatic heart, pharyngitis, and normal populations 
remains speculative until many more individuals are tested. Furthermore 
whether these observations would be maintained after cross absorbtion 
studies of the sera with M proteins, also remains speculative but 
should be examined in future studies. 
A further comparison of the three groups of sera was performed 
by selecting a high titer for each antigen and calculating what per-
centage of individuals within the three groups manifested an equal or 
greater value than the selected titer. The results of this comparison 
. 
are found in Table XIV. It is probably of significance that a greater 
percentage of rheumatic heart patients than normal or pharyngitis pos-
sessed an equal or higher titer than the selected titer for every M 
protein and the group A polysaccharide. Such an observation clearly 
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indicates anti M protein and APS antibody levels in convalescent 
rheumatic heart patients. Since these rheumatic heart patients were 
probably infected during the course of their illness by one of the 
streptococcal M-type but not by each of the different M types tested 
here, this is further evidence that cross reactivity between M types 
can exist following a streptococcal infection. 
Also from Table XIV a comparison of normal sera to pharyngitis 
sera showed that a greater percentage of pharyngitis patients possessed 
high titers to APS, Ml, and M6, but that a greater percentage of 
normal sera have high titers to M3 and M4. Since the pharyngitis group 
showed elevated titers to Ml and M6, the etiological agent responsible 
for this group's illness possibly was streptococcus of the Ml or M6 
types. However, in a later analysis performed by means of the "T-test" 
it was shown that there did not exist a significant difference between 
the anti Ml levels of normal and pharyngitis sera. Therefore the most 
probable candidate as the etiological agent for these pharyngitis 
patients would then be the M6 type streptococci. Also the finding that 
the titer to APS was elevated over normal in both pharyngitis and 
rheumatic heart sera indicated that higher than normal levels of anti 
APS are manifested in most streptococcal infected adults. Whether the 
observation that more normal sera possessed higher titers to M3 and 
M4 than the pharyngitis sera reflects a deficiency in the capacity of 
pharyngitis patients to develop equally high titers to these proteins 
isn't known. Also whether this slight deficiency is at all responsible 
for subsequent streptococcal infection also remains speculative. 
' 
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The geometric mean titers of rheumatic heart, pharyngitis, and 
normal sera were used to show by means of the "T-test" whether or 
not there existed significant differences between the three populations. 
From Table XVIII it can be seen that except for Ml and Ml2 there was 
a significant difference at the 1% level for the geometric mean titers 
of each M protein and APS between normal and pharyngitis sera. This 
comparison revealed that normal serum and pharyngitis serum could not 
be distinguished by their Ml and Ml2 titers which is an indication that 
type Ml or Ml2 streptococci were not involved as the etiological 
agents responsible for pharyngitis in these patients. It is of 
significance that M3, M4, MS, Ml4, and M29 manifested higher titers in 
normal serum than in pharyngitis serum. This information coupled 
with the fact that the geometric mean of the combined M proteins was 
significantly higher in normal than in pharyngitis serum was unexpected. 
Since these convalescent pharyngitis patients had confirmed streptococcal 
infections and since cross reactions between anti M protein and M protein 
occur, it was thought that the pharyngitis patients would have displayed 
higher than normal titers to most M proteins. Contrary to anti M 
protein levels, pharyngitis sera possessed significantly higher anti 
APS levels than those found in normal sera. These patients therefore 
possessed higher than normal titers to the group specific polysaccharide 
but lower than normal titers to most of the type specific M proteins 
tested. 
A comparison between rheumatic heart and normal sera was also 
shown in Table XVIII. Except for M3 which manifested a higher titer in 
normal sera and M4 which was not significantly different between these 
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two groups, the M proteins and APS showed significantly higher titers 
in sera from rheumatic heart patients than in normal sera. It should 
also be noted that of the streptococcal antigens tested, only M3 
manifested a significantly higher titer in normal sera than in either 
pharyngitis or rheumatic heart sera. 
Table XVIII also depicts significant differences observed for 
anti-streptococcal titers between the pharyngitis and rheumatic heart 
group. Titers to the group A polysaccharide were not significantly 
different between these two groups. This finding was not surprising 
since infection with any M type of a group A streptococci should elevate 
the serum anti-APS level. The mean anti-APS level was elevated over 
normal (1:329) in rheumatic heart (1:2254) and in pharyngitis (1:3141). 
Of the M proteins, only M3 and M6 protein failed to demonstrate 
significantly different mean titers between the rheumatic heart and 
pharyngitis groups. 
Before the discussion of the reaction between erythrocytes and 
human sera can be undertaken, it must be ascertained whether or not the 
well known reaction between Forssman antigen and antibody was manifested 
in this study. Humans of blood group type A and AB possess Forssman 
antigen on their erythrocytes whereas humans with blood type B and 0 
do not (2). Therefore serum from humans of blood type A or AB should 
. 
not contain anti-Forssman antibody since, if present, autoimmune 
disorders would prevail. Humans of blood group B and 0 contain anti-A 
antibody in their sera. People of this blood type also contain natural 
hemolysin for sheep erythrocytes (27) which are known to possess Forssman 
r 
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antigen. This reaction may depend upon the anti-A antibody recognizing 
the Forssman antigen on sheep erythrocytes since blood group substance 
A and Forssman antigen are closely related (27). Using this assumption 
that type A and AB human sera lack anti-Forssman antibody and type B 
and 0 human sera contain such antibody, it can be determined whether 
or not Forssman antigen-antibody reactions are present between these 
sera and erythrocytes known to contain or lack the Forssman antigen. 
Erythrocytes of sheep, chicken, and goat contain Forssman antigen 
whereas Porcine, rabbit, human 0-, duck, rat, and bovine erythrocytes 
do not. Whether or not erythrocytes of turtle, guinea-pig, horse, 
.. 
and dog possess this antigen isn't known, however these animals do 
contain the antigen in their tissues. Geometric mean titers calculated 
to compare the responses of Types A and AB sera to types B and 0 
indicated no significant differences between these sera when titered 
with sheep, chicken, and goat erythrocytes. Since types A and AB sera 
do not contain Forssman antibody and types B and 0 probably do there 
should have been significant differences between the responses of these 
sera to these erythrocytes. Moreover rabbit and porcine erythrocytes 
which do not contain the Forssman antigen both manifest significantly 
higher titers in normal sera than do the erythrocytes possessing this 
antigen. Why the Forssman reaction was not portrayed in this system 
can only be speculated upon. One initial assumption was that stabilized 
erythrocytes were sufficiently different from corresponding untreated 
ones. However the human A, B, 0 system was not altered after aldehyde 
stabilization of human type A, B, and O erythrocytes as determined by 
r 
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reacting such cells with specific human anti-A and anti-B sera. 
Another possibility was that these human sera did not contain Forssman 
antibody at a level capable of distinguishing between erythrocytes 
with or without Forssman antigen. Still another possibility was that 
all Forssman positive animals may not possess the antigen in equal 
quantity within their particular species and the specific animals 
selected for this study may contain low amounts of the antigen on 
their erythrocytes. Nevertheless there appears to be no correlation in 
this study between reactions of erythrocytes with normal sera and the 
Forssman reaction. 
By means of the Duncan multiple range test (Tables XI, XII, and 
XIII) it was shown that not all erythrocytes reacted with human serum 
to the same degree. It is of significance that such a wide range of 
titers (<8 to 1:4096) existed between the lowest and highest titers of 
the different erythrocytes. Of further significance is the finding 
that so many of the erythrocytes displayed significantly different titers 
rather than manifesting nearly identical reactivities in these sera. 
Because of the different reactions baby chick and adult chicken 
erythrocytes manifest with rubella virus it was thought that stabilized 
erythrocytes from these two sources might differ in their reactivities 
to the sera tested here. However no difference in reactivity could 
' be shown as can be seen from Tables XI, XII and XIII in which these 
erythrocytes did not portray significantly.different titers in any of 
the three groups of sera tested. 
Tables III, V, and VII present the data obtained when the various 
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stabilized erythrocytes were used to titer the sera from normal, 
pharyngitis, and rheumatic heart individuals respectively. This informa-
tion was used to calculate the geometric mean titers for these three 
groups of sera, which appear in Table XV, XVI, and XVII. From Table 
XV it can be seen that half of the erythrocytes tested with normal 
serum were agglutinated even when the sera were diluted >1:100. These 
erythrocytes were from rabbit, porcine, duck, rat, guinea pig, horse, 
and dog. Obviously the high titers in normal sera to these erythrocytes 
were not obtained by sensitization of the normal population with these 
cells. A more probable explanation is that the surface of these erythro-
cytes contain antigenic determinants similar or identical to determinants 
found on substances to which humans have been sensitized. Such sub-
stances could be of bacterial, viral, or even plant origin. Until these 
substances can definitely be shown to induce antibodies in man which 
cross react with surface antigens of various erythrocytes these antibodies 
are still considered as naturally occurring. This natural immunity, 
or antibodies appearing without obvious external stimulus, is not 
peculiar to man nor to antibodies against erythrocytes. Porcine and 
rabbits possess natural antibodies to erythrocytes of sheep and humans 
(3). Fisher (6) observed that human gamma globulin was effective in 
mouse protection studies against bacteria such as Ps. aeruginosa, E. coli, 
. 
Proteus, Klebsiella, Staph. aureus, Strep. salivarius, Strep. pneumonia, 
and Strep. pyogenes group A. The present observations on the passive 
hemagglutinating ability of normal human sera to M-proteins and APS 
is in correlation with the results Fisher observed for Strep. pyogenes 
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group A. Tables XVI and XVII present the geometric mean titers 
obtained when the erythrocytes were reacted with sera from the pharyngitis 
and rheumatic heart patients. There is an indication from the data in 
these tables that streptococcal infections results in elevated antibody 
titers to various stabilized erythrocytes. For example, when the 
geometric mean titers of normal sera (Table XV) are compared with the 
mean titers of pharyngitis sera (Table XVI) it can be seen that the 
mean titers are elevated in the sera of pharyngitis patients to 
stabilized erythrocytes of porcine, sheep, duck, baby chick, chicken, 
rat, horse, dog, goat, and bovine. In other words all erythrocytes 
except those from rabbit, human, guinea-pig, and turtle manifested 
higher than normal geometric mean titers in pharyngitis patients. 
This same difference with the added fact that guinea pig was elevated 
over normal in rheumatic heart could be seen when the geometric mean 
titers for normal and rheumatic heart sera were compared (Tables XV 
and XVII). This obvious increase in reactivity to erythrocytes by 
streptococcal infection can be seen more vividly in Table XIV which 
compares the erythrocyte reactions for the three groups of sera by 
indicating the percentage of each group that exceeds or equals a 
selected high titer. Except for the finding that the normal group 
contained a greater percentage of individuals than the pharyngitis group 
whose titers to FPPE, FPBCE, and FPGPE exceeded the selected high 
titer, the data in Table XIV agrees with the comparison made between 
the geometric mean titers. A striking difference between normal and 
streptococcal infected sera can be seen from this data. When titers 
106 
to horse, dog, goat, and bovine are compared between normal and con-
valescent serum it can be seen that a substantially greater percentage 
of the convalescent sera possess high titers to these erythrocytes 
than do normal sera. It appears from this data that bovine, horse, 
goat, and dog erythrocytes would be the best candidates for distinguishing 
between normal sera and sera from patients with streptococcal infections. 
By the same criteria erythrocytes of turtle, guinea pig, porcine, 
and baby chick appear to distinguish rheumatic heart sera from 
normal and pharyngitis sera. From this data it doesn't appear that 
any of the erythrocytes tested are capable of distinguishing pharyngi-
tis sera from both rheumatic heart and normal sera. 
By means of the T-test (Table XVIII) some of the differences 
observed between normal and infected sera have been shown to be signi-
ficant. Pharyngitis serum contained significantly higher than normal 
geometric mean titers to all erythrocytes except those of rabbit and 
guinea pig both of which showed no significant difference between the 
two groups of sera. Rheumatic heart sera contained significantly 
higher than normal geometric mean titers to all erythrocytes with the 
single exception that .rabbit erythrocytes manifested a significantly 
lower than normal geometric mean titer in rheumatic heart serum. One 
further observation from Table XVIII is that only five of the fourteen 
erythrocytes tested showed significantly different geometric mean titers 
between rheumatic heart and pharyngitis serum. Erythrocytes of human, 
rat, horse, and goat showed significantly higher titers in pharyngitis 
sera whereas erythrocytes from dog gave a significantly higher titer in 
r 
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rheumatic heart serum. 
It would be premature at this time to select one erythrocyte 
and attribute to it the task of differentiating between these three 
groups of sera. Many more serum samples from each population would 
need to be tested and cross absorption studies would have to be per-
formed to confirm any positive results. However the comparative data 
collected on the reactivity between these three groups of sera to the 
erythrocytes of bovine, horse, goat, and dog clearly indicates that 
these erythrocytes are agglutinated by the serum of streptococcal 
infected patients but not nearly as frequently or intensely in normal 
sera. Employing stabilized heterologous erythrocytes has not provided 
for any rational correlates to the anti-M protein profile in human 
serum. From the work of Springer (24) one can assume that the main 
source of connnon antigenic determinants between erythrocytes and strep-
tococci will be in the bacteria's membrane. Further, since M proteins 
do not contain carbohydrate, the lack of correlation is not surprising. 
However, a correlation may exist between elevated anti-APS levels in 
these patients and corresponding higher titers to heterologous erythro-
cytes. The anti-APS levels in pharyngitis and rheumatic heart sera 
are significantly higher than normal as substantiated by the T-test in 
Table XVIII. Likewise, all anti-erythrocyte titers are either signi-
. 
ficantly higher or equal to normal levels in the serum of pharyngitis 
patients. The same correlation exists in rheumatic heart patients which 
show significantly higher than normal anti-erythrocytes titers to all 
but the rabbit erythrocyte. This correlation has merit since the APS 
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molecule and the erythrocyte surface are mainly carbohydrate. However, 
this correlation cannot be fully substantiated without careful cross 
absorption studies with the various erythrocytes and APS. 
One other correlation may be drawn between the anti streptococcal 
antigen profile and serum reaction with erythrocytes. It is interesting 
that rheumatic heart, pharyngitis, and normal sera each possessed geo-
metric mean titers to human 0- erythrocytes that were significantly 
different from each other. It is known that autoimmune disorders 
such as hemolytic anemia, glomerulonephritis and rheumatic fever 
(20) can be a sequela to certain streptococcal infections. Not only 
does the agglutination of human 0- erythrocytes indicate such a disorder 
in the patients tested here but also the finding that 100% of the 
rheumatic heart and 70% of the pharyngitis sera tested possess antibody 
titers >8 against HGG-FPHE o- while only 8% of the normal sera 
possess a comparable titers (Table XIV). Also by means of the T-test 
it is shown that a highly significant difference does exist between 
normal sera and the sera of rheumatic heart and pharyngitis patients 
when titered with HGG-FPHE 0-. 
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